Home Biographical Sketch Awards & Distinctions Intellectual Property Advisory 
Boards
Invited Presentations National & International Activities Publications Index & List Books
ELISA Testing -- A Regulatory Revolution World Racing Rules on Equine Medications
 
Thomas Tobin
Publications/Books/Symposia/Research/Papers
  • 340-plus papers. Index and Listing are below.  The listing does not include papers published prior to 1975 mostly in the area of the biochemical pharmacology of sodium transport and Na-K-ATPase.
    (Click HERE for papers prior to 1975)
  • 100-plus abstracts, two books, four volumes of proceedings. Numerous articles published and reprinted in lay journals..
  • Drugs and the Performance Horse, by Thomas Tobin. Foreword by HRH, The Duke of Edinburgh. 480 pp., Springfield, Illinois: Charles C. Thomas, 1981.
  • Equine Drugs and Vaccines: A Guide for Owners and Trainers, Eleanor Kellon with Thomas Tobin. 336 pp., Breakthrough Press, 1994.
  • Proceedings of the Workshop on Testing for Therapeutic Medications, Environmental and Dietary Substances in Racing Horse. 218 pages, 1995.
  • Furosemide in the Horse: Its Actions, Effects, and Regulatory Control.  Proceedings of a Testing Integrity Program Workshop and Seminar, 124 pages, Wind Publications, 2000.
  • World Rules for Equine Drug Testing and Therapeutic Medication Regulation: 2012 Policy of the National Horsemen's Benevolent and Protective Association. Thomas Tobin, Kimberly Brewer, and Kent H. Stirling.  Wind Publications, 2012.

   

Click on the book for further information:

Publications Subject Index & Publications List

1975 to 2003

SUBJECT Lab
Paper #
Year published
ACEPROMAZINE 
Atypical conditions/ quantitative recovery 61 1981
Blockage of fentanyl locomotor response 73 1982
Pharmacology & behavior (variable interval) 74 1981
Pharmacokinetics & pharmacology 78 1982
ELISA & PCFIA detection 144 1988
ELISA detection 150 1988
Non-isotopic immunoassays (review) 156 1989
Hematocrit values as threshold indicator 172 1992
Effects on spontaneous locomotor activity 250 1997
ACIDIFICATION OF URINE
Population distribution & methods 139 1990
Population parameters & methods 151 1988
ACUPUNCTURE
Influence on pain threshold 273 1999
AGONISTS,  a2-
Detection of detomidine by RIA 153 1989
Detomidine clearance by ELISA 180 1992
Immobilization of goats using detomidine 210 1997
Amitraz, detomidine and locomotor activity 224 1997
Antinociception & sedative effect of amitraz 231 1998
Amitraz, detomidine, acepromazine and activity 250 1997
Serum concentrations, effects of oral detomidine 271 2002
Biotransformation, pharmacokinetics of guanabenz 289 2003
Comparative clinical effects, pharmacodynamics 290
Pharmacodynamics of guanabenz and related ... 299
ELISA assay for guanabenz 314
Detection and confirmation method for amitraz 322
ELISA assay for guanabenz 333
ALBUTEROL (TORPEXョ)
ELISA detection times 295 2002
ELISA detection times, preliminary report 297
ALFENTANIL (ALFENTAョ)
RIA & ELISA detection 148 1988
ELISA & RIA detection 155 1989
AMANTADINE
Pharmacology and pharmacokinetics  209 1996
Overview of pharmacology, side effects 227 1996
Preliminary report: pharmacokinetics 246 1995
AMITRAZ
Effect on spontaneous locomotor activity 224 1997
Antinociception & sedative effect 231 1998
Locomotor activity  250 1997
Detection and confirmation method 322
ANABOLIC STEROIDS
Androgen group of drugs 26 1978
Use & excretion data 169 1989
ANALGESICS
Furosemide & pentazocine urinary concentration 18 1977
Furosemide & pentazocine disposition 22 1978
Detection & pharmacokinetics of pentazocine 27 1979
Detection of pentazocine & fentanyl 31 1979
Opiate receptor 32 1978
Locomotor effects/ fentanyl & apomorphine 38 1979
Six drugs: morphine, meperidine, pentazocine, etc 39 1979
Quantitation & blockage/ locomotor response 40 1978
Selective blockage/ locomotor response 46 1981
Review: non-steroidal anti-inflammatory drugs 55 1979
Pharmacokinetics & locomotor response of fentanyl 59 1979
Detection of morphine (GC) 65 1981
Method for pain perception 104 1985
Autonomic & behavioral response of fentanyl 106 1985
 -Opioid receptor narcotics 110 1985
RIA screening (3H) of fentanyl 123 1986
RIA screening (123I) of fentanyl 126 1986
Detection & pain measurement 127 1989
Pharmacology of methylated analogs of fentanyl 133 1989
Review of fentanyl 134 1988
PCFIA detection of fentanyls 136 1987
RIA, PCFIA & ELISA detection 137 1987
ELISA detection of fentanyls 140 1988
RIA & ELISA detection of fentanyls, alfentanil 148 1988
Detection of detomidine by RIA 153 1989
ELISA & RIA detection of fentanyls, alfentanil 155 1989
Tranquilizers, local anesthetics and... 168 1989
Detomidine clearance by ELISA 180 1992
Immobilization of goats using detomidine 210 1997
Amitraz, detomidine and locomotor activity 224 1997
Antinociception & sedative effect of amitraz 231 1998
Lack of anesthetic efficacy of fentanyl in abaxial sesamoid block model 245 1999
Amitraz, detomidine, acepromazine and activity 250 1997
Detection of remifentanil 270 2000
Serum concentrations, effects of oral detomidine 271 2002
Detection of metabolite of remifentanil  280 2000
ELISA detection of remifentanil  283 2000
Biotransformation, pharmacokinetics of guanabenz 289 2003
Comparative clinical effects, pharmacodynamics 290
Pharmacodynamics of guanabenz and related ... 299
ELISA assay for guanabenz 314
Detection and confirmation method for amitraz 322
ELISA assay for guanabenz 333
ANILERIDINE
Behavioral response (foot-step counts) 39 1979
Locomotor response 59 1979
ANTIBIOTICS
Chemotherapy in the horse 35 1978
Review: streptomycin, gentamicin, etc 52 1979
Overview in equine medicine 60 1979
AORC
Uniform drug classification guidelines 256 1998
APOMORPHINE
GC detection 7 1976
TLC method 36 1978
Locomotor response 38 1979
Locomotor response 59 1979
Enzyme hydrolysis & TLC detection 70 1982
Locomotor activity 250 1997
ELISA assay  315
AZAPERONE (STRESNILョ)
Metabolite identification 178 1996
ELISA detection 181 1992
BEHAVIOR CHAMBER
Locomotor quantitation of medications 217 1996
Development and characterization of; also effects of amitraz, detomidine 224 1997
Development and locomotor activity; amitraz, detomidine, acepromazine 250 1997
BEHAVIOR RESPONSE
Procaine: Observed excitation 5 1977
Procaine: Observed excitation 10 1976
Methylphenidate: Variable interval training 20 1981
Pentazocine & fentanyl: Locomotor 31 1979
TLC method for pentazocine 36 1978
Narcotic analgesics: Locomotor, eating  39 1979
Reserpine: Locomotor 42 1979
Reserpine: Locomotor 43 1978
Reserpine & Cocaine: Variable interval training 58 1979
Narcotic analgesics: Locomotor 59 1979
Review of behavioral models 73 1982
Acepromazine: Variable interval training  74 1981
Acepromazine: Variable interval training 78 1982
Caffeine: Locomotor, enhanced fentanyl response 83 1983
Clenbuterol: Locomotor 94 1983
Fentanyl: Skin twitch/ hoof withdrawal latency 106 1985
Ethylketazocine: Skin twitch/ hoof withdrawal 107 1986
U50,488H: Skin twitch/ hoof withdrawal, locomotor 125 1988
Hordenine: Variable interval training, flehman 129 1990
DADA: Observed responses 135 1988
Locomotor quantitation of medications 217 1996
Cocaine: Locomotor 222
Quantitation of locomotor effect 224 1997
BENZOCAINE (ETHYL AMINOBENZOATE)
Highest no-effect dose determination 189 1996
Local anesthetic efficacy 190 1994
Highest no-effect dose  247 1995
BENZOYLECGONINE
ELISA detection 176 1991
ELISA detection 194 1996
Detection & significance 214 2000
BUMETANIDE (BUMEXョ)
Use in horses 14 1977
ELISA detection 158 1994
BUPIVACAINE
Highest no-effect dose 189 1996
Local anesthetic efficacy 190 1994
Pharmacological effects & analytical detection 234 1999
Detection of 3-hydroxybupivacaine 239 1998
Highest no-effect dose  247 1995
BUPRENORPHINE (BUPRENEXョ)
ELISA detection (in review) 156 1989
BUTORPHANOL (STADOLョ)
Enzyme hydrolysis & TLC detection 70 1982
Locomotor response 73 1982
CAFFEINE
Pharmacology, pharmacokinetics & behavior 83 1983
Interpretation of positive results 203 1994
Methylxanthines in the horse 211 1998
ELISA development 216 1996
Locomotor activity effects 235 2001
Quantitation by ELISA vs GC 267 2001
CARFENTANIL (WILDNILョ)
PCFIA detection 136 1987
RIA, PCFIA & ELISA detection 137 1987
ELISA detection 140 1988
RIA & ELISA detection 148 1988
ELISA & RIA detection 155 1989
Immobilization of goats 210 1997
CASSAINE
Interaction with Na+K+-ATPase 19 1977
CELECOXIB
Qualitative identification 269
Identification and disposition 277 2000
CHLORAMPHENICOL
Interaction with phenylbutazone metabolism 6 1977
CHLORPROMAZINE (THORAZINEョ)
Atypical conditions/ quantitative recovery 61 1981
Cross-rectivity with acepromazine ELISA 144 1988
Cross-rectivity with acepromazine ELISA 150 1988
CLEARANCE TIMES
Pentazocine 27 1979
Pentazocine, fentanyl 31 1979
Urinary drug concentrations 33 1978
Reappraisal 71 1982
Clenbuterol 94 1983
Drugs in horses 165 1989
Pyrantel tartrate 175 1991
Detomidine 180 1992
HBPA Proposed National Policy on Drug Testing and Therapeutic Medication 330 2003
World rules on clearance times 335
CLENBUTEROL
Clearance times & behavioral effects 94 1983
Behavior chamber 265
ELISA & GC/MS detection (IT dose) 268 2000
Urinary concentrations: ELISA & GC/MS 274 2001
LC/MS/MS quantitation in serum 275 2001
Method for detection in serum 281 2000
Synthesis of deuterated standard & metabolites 284 2000
COCAINE
Variable interval conditioning response 58 1979
Locomotor & head bowing responses 73 1982
PCFIA detection 152 1989
ELISA detection 176 1991
Highest no-effect dose determination 189 1996
Local anesthetic efficacy 190 1994
ELISA and GC/MS quantification 194 1996
Interpretation of positive results 203 1994
Behavior, ELISA & GC/MS 222
Benzoylecgonine detection 214 2000
Highest no-effect dose  247 1995
LC/MS/MS method 282 2000
Highest no-effect dose, elimination pattern 310 2002
Hepatotoxicity 329 1992
COLORIMETRY
Procaine method 2 1976
Procaine method 3 1976
Procaine method 4 1977
Procaine method 5 1977
Procaine method 15 1977
COTININE
ELISA detection 177 1993
Cross-rectivity with hydroxycotinine ELISA 183 1996
CORTICOSTEROIDS
Review 45 1979
Pharmacology in the horse 63 1980
Anti-inflammatory agents 163 1989
Clinical use & characteristics 185 1993
CYANIDE
Analytical detection and "normal" population data 298
Spectrophotometric detection method 306 2003
Toxicokinetics in the horse 307
Pharmacokinetics of cyanide and mandelonitrile; relevance to MRLS 309
Cherry trees, plant cyanogens, caterpillars and MRLS 316 2003
DETECTION TIMES
Reappraisal 71 1982
Uncertainty 119 1986
Drugs in racing horses 165 1989
Pyrantel tartrate 179 1992
Albuterol 295 2002
Albuterol 297
Factors affecting detection times for NSAIDS (presentation) 326
HBPA Proposed National Policy on Drug Testing and Therapeutic Medication 330 2003
World rules on detection times 335
DETOMIDINE (DOMOSEDANョ)
Variable interval conditioning response 132 1988
RIA detection 153 1989
ELISA detection 180 1992
Immobilization of goats 210 1997
Locomotor activity 250 1997
Delivery mediums and serum concentrations 271 2002
DEUTERATED COMPOUNDS
Synthesis of clenbuterol analog 284 2000
Synthesis and characterization of deuterated furosemide 301
DICLAZURIL
Detection and pharmacokinetics 240 1998
Identification, detection & pharmacokinetics 242 1999
... and EPM 248 1997
Preliminary pharmacokinetics 249 1997
Clinical report 254 2000
EPM therapy 286 2001
Sodium salt formulation 294
DIETARY SUBSTANCES
Significance of dietary anthelmintic pyrantel tartrate 175 1991
Interim report on 1994 workshop 194 1996
1994 Workshop Proceedings 200 1995
Fifties rules, nineties testing 202 1995
Overview of regulatory concern 208 1995
Dietary, environmental and endogenous substances 212 1998
Workshop outcomes 223 1996
Poisoning in horses 226 1997
HBPA Proposed National Policy on Drug Testing and Therapeutic Medication 330 2003
DIISOPROPYLAMINE DICHLOROACETATE (DADA)
Detection (GC), pharmacokinetics & behavior 135 1988
DRUG TESTING (GENERAL)
Testing for drugs in horses 44 1978
Drugs and performance testing in racing horses 54 1979
Testing for drugs in horses 111 1986
EFFICACY AND COST OF TESTING (GENERAL DRUG TESTING)
Illegal medications 97 1985
Illegal medications 115 1985
Drug testing 121 1986
Non-isotopic immunoassays (review) 156 1989
Testing for drugs and medications 201 1995
Equine drug testing 206 1998
Consequences of highly sensitive drug testing 233 1997
The need for limitations on the sensitivity of testing for certain agents 243 1998
Testing for therapeutic medications, analytical/pharmacological relationships 244 1999
Past and future of drug testing, medication regulation (presentation) 325
Pre-purchase and drug testing (presentation) 327
HBPA Proposed National Policy on Drug Testing and Therapeutic Medication 330 2003
"Test of Time" re: ELISA testing (1990 Blood-Horse article) 334 1990
ELECTRO-ACUPUNCTURE
Influence on pain threshold 273 1999
ELISA
Carfentanil 137 1987
Morphine 138 1988
Fentanyl & congeners (methylfentanyls) 140 1988
Mazindol 141 1988
Furosemide 143 1988
Acepromazine 144 1988
Furosemide 146 1988
Mazindol 147 1988
Fentanyl & fentanyl derivatives 148 1988
Morphine 149 1988
Acepromazine 150 1988
Phenylbutazone 154 1989
Fentanyl, alfentanil, sufentanil, carfentanil 155 1989
Review 156 1989
Ethacrynic acid & bumetanide 158 1994
Pre-race testing 160 1988
Post-race testing 161 1988
Backgrounds, sensitivity, pooling, no. of tests 162 1990
Equine medication control 171 1989
Morphine & etorphine 173 1991
Benzoylecgonine & cocaine 176 1991
Cotinine 177 1993
Detomidine 180 1992
Azaperone 181 1992
Procaine 182 1992
trans-3'-Hydroxycotinine 183 1996
Cocaine quanitification 194 1996
Remifentanil (Fentanyl Group) 283 2000
Caffeine 216 1996
Flunixin 219 1996
Methocarbamol 220 1996
Cocaine quanitification 222
Lidocaine identification 261 2000
Caffeine: ELISA vs GC 267 2001
Urinary concentrations of clenbuterol 274 2001
Fentanyl group ELISA for detection of remifentanil, other narcotic analgesics 283 2000
Stanozolol 288 2000
Guanabenz 289 2003
Albuterol 295 2002
Albuterol 297
Amphetamine 312
Ketamine 313
Guanabenz 314
Apomorphine   315
Guanabenz 333
Overview of testing 334 1990
ENDOGENOUS SUBSTANCES
Workshop Proceedings 200 1995
Fifties rules, nineties testing 202 1995
Overview of regulatory concern 208 1995
Dietary, environmental and endogenous substances 212 1998
Workshop outcomes 223 1996
HBPA Proposed National Policy on Drug Testing and Therapeutic Medication 330 2003
ENDOTOXIC SHOCK
Effects of naloxone 79 1984
 -Phenylbutylnitrone effect on endotoxin toxemia 205 1997
ENKEPHALINS
Locomotor activity 80 1982
ENVIRONMENTAL ASSURANCE
Release from petroleum storage tanks 207 1995
ENVIRONMENTAL SUBSTANCES
Workshop Proceedings 200 1995
Fifties rules, nineties testing 202 1995
Overview of regulatory concern 208 1995
Dietary, environmental and endogenous substances 212 1998
Workshop outcomes 223 1996
Poisoning in horses 226 1997
HBPA Proposed National Policy on Drug Testing and Therapeutic Medication 330 2003
ERGOT ALKALOIDS
Analysis by electrospray tandem quadrupole MS 296
Screening by HPLC-electrospray [+] MS 305
EQUINE INFLUENZA
Pharmacology, pharmacokinetics & neurological effects of amantidine 209 1996
Therapeutic efficacy of rimantidine 218 1999
Chemotherapy for 227 1996
Efficacy of rimantadine 251 1997
EQUINE PROTOZOAL MYELOENCEPHALITIS (EPM)
Detection and pharmacokinetics of diclazuril 240 1998
Interim report on workshop 241 1998
Detection and pharmacokinetics of diclazuril 242 1999
Diclazuril and ... 248 1997
Clinical report 254 2000
Complicating factors in diagnosing 258 1999
Therapeutic approaches 286 2001
Sodium salts of diclazuril & toltrazuril sulfone 294
ETHACRYNIC ACID (SODIUM EDECRINョ)
ELISA detection 158 1994
ETHYLKETAZOCINE
Nociception, behavior & autonomic response 107 1986
ETORPHINE (M99ョ)
Locomotor response 59 1979
RIA screening (3H) 112 1986
RIA screening (3H) 113 1985
TLC detection 122 1985
RIA detection (123I) 131 1988
ELISA detection 173 1991
EXERCISE-INDUCED PULMONARY HEMORRHAGE (EIPH)
Pharmacology & therapeutics 64 1980
Medication 164 1989
Findings I 184 1992
Findings II 187 1992
Findings III 188 1992
Nitroglycerin and racing horses 196 1995
Review of etiology & pathogenesis 204 1997
EXPERT WITNESS
Experiences 114 1986
FEED POISONING
Poisoning in horses 226 1997
FENTANYL (SUBLIMAZEョ)
Detection, pharmacokinetics, & behavior 31 1979
Locomotor effects 38 1979
Pharmacokinetics & behavior (locomotor response) 59 1979
Autonomic & behavioral response 106 1985
RIA screening (3H) 123 1986
RIA screening (123I) 126 1986
Methylated analogs: detection & pharmacology 133 1989
Review 134 1988
PCFIA detection 136 1987
ELISA detection 140 1988
RIA & ELISA detection 148 1988
ELISA & RIA detection 155 1989
Lack of anesthetic efficacy of fentanyl in abaxial sesamoid block model 245 1999
FENTANYL GROUP ELISA
Detection of remifentanil 283 2000
FLUNIXIN MEGLUMINE (BANAMINEョ)
Review: non-steroidal anti-inflammatory drugs 55 1979
Pharmacology 81 1982
ELISA detection 219 1996
FORCE PLATE
Designing of drug thresholds 279 2000
FORENSIC CHEMISTRY
Significance of pyrantel tartrate 175 1991
FUROSEMIDE (LASIXョ)
Effects on phenylbutazone urinary concentrations 9 1976
Review 17 1977
Effects on pentazocine urinary concentrations 18 1977
Review 21 1977
Detection, pharmacokinetics & clearance 23 1978
Dose & time responses 24 1978
Overview 25 1977
Detection & pharmacology 41 1978
Review 50 1978
Reduction of urinary drug concentrations 68 1981
...,  -Glucuronidase & drug detection 70 1982
Pharmacokinetics & blood levels 84 1983
Pharmacokinetics & blood levels 92 1983
Testimony on drug testing 95 1983
ELISA & PCFIA detection 143 1988
ELISA & PCFIA detection 146 1988
Non-isotopic immunoassays (review) 156 1989
Actions, effects & control (TIP) 259 2000
Specific gravity & osmolality of urines 285 2000
Synthesis and characterization of deuterated std. 301
Detection, quantification, and pharmacokinetics after IV admin 302
Effects on urinary specific gravity following IV administration 317
GAS CHROMATOGRAPHY
Procaine detection, ECD 5 1977
Phenylbutazone detection, FID 6 1977
Apomorphine detection, ECD 7 1976
Phenylbutazone detection, FID 9 1976
ECD and equine drug testing 11 1976
Procaine detection, ECD 15 1977
Pentazocine detection, NPD 18 1977
Methylphenidate detection, ECD 20 1981
Furosemide detection, ECD 23 1978
Pentazocine detection, NPD 27 1979
Acepromazine, chlorpromazine detection, NPD 61 1981
Morphine detection, ECD 65 1981
Morphine detection, ECD 67 1982
Morphine, phenylbutazone detection, ECD 68 1981
Morphine detection, ECD 76 1983
Flunixin detection, NPD 81 1982
Caffeine detection, NPD 83 1983
Furosemide detection, ECD 84 1983
Furosemide detection, ECD 92 1983
Clenbuterol detection, NPD 94 1983
Hordenine detection, NPD 129 1990
DADA detection, NPD 135 1988
Caffeine: ELISA vs GC 267 2001
GAS CHROMATOGRAPHY/ MASS SPECTROSCOPY
Cocaine quanitification 194 1996
3-Hydroxylidocaine 228 1998
3-Hydroxymepivacaine 229 1999
3-Hydroxybupivacaine 234 1999
Isoxsuprine determination 263
Clenbuterol urinary concentrations 274 2001
GENTAMICIN
Pharmacology review 52 1979
GLUCURONIDE METABOLITES
Effects of furosemide on pentazocine glucuronide 18 1977
Morphine glucuronide enzyme hydrolysis 67 1982
TLC drug detection with enzyme hydrolysis 70 1982
Identification of hydroxyropivacaine glucuronide metabolite by ESI+/MS/MS 255 2000
Direct MS-MS identification of isoxsuprine glucuronide 256 1998
GOLDENSEAL (HYDRASTIS)
...And morphine detection 72 1981
GUANABENZ
Detection, biotransformation, pharmacokinetics 289 2003
Comparative clinical effects 290
Pharmacodynamics of ... and related  a-2 agonists 299
ELISA assay 314
ELISA assay 333
HEMATOCRIT
Effects of acepromazine 74 1981
Effects of acepromazine 78 1982
Drug threshold indicator 172 1992
HIGHEST NO-EFFECT DOSE (HNED)
Hematocrit as drug threshold indicator 172 1992
For local anesthetics 189 1996
Review of methodologies 193 1994
Procaine, cocaine, bupivacaine, benzocaine 247 1995
Overview of no-effect levels 287 2001
Cocaine 310 2002
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
Oxyphenbutazone determination 87 1983
Phenylbutazone, oxyphenbutazone, & metabolite 93 1983
Phenylbutazone concentration determination 96 1984
Phenylbutazone concentration determination 99 1985
Procaine determination in post-race urine 197 1996
Ergot alkaloids screened by HPLC-electrospray[+] tandem quadrupole mass spectrometry 305
HOOF WITHDRAWAL/ SKIN TWITCH LATENCY
Fentanyl 106 1985
Ethylketazocine 107 1986
U50,488H 125 1988
HORDENINE
Pharmacology, pharmacokinetics & behavior 129 1990
HUMAN DRUGS OF ABUSE
Fentanyl RIA screening in human urine 126a
PCFIA screening 145 1988
Review of non-isotopic immunoassay 156 1989
HYDROMORPHONE (DILAUDIDョ)
TLC method 36 1978
Behavioral response (foot-step counts) 39 1979
Locomotor response 59 1979
Enzyme hydrolysis & TLC detection 70 1982
HYDROXYBUPIVACAINE, 3-
Detection of 3-hydroxybuvacaine 239 1998
HYDROXYCOTININE, trans-3'-
Cross-reactivity with cotinine ELISA  177 1993
ELISA detection 183 1996
HYDROXYMEPIVACAINE, 3-
Detection of 3-hydroxymepivacaine 237 1998
HYDROXYPHENYLBUTAZONE
Effect of urine pH on concentration & HPLC 93 1983
IMIPRAMINE
Effect on platelet uptake of serotonin 30 1979
INFLUENZA, EQUINE
Amantadine in prophylaxis and treatment 209 1996
Pharmacology, pharmacokinetics & neurological effects of amantidine 209 1996
Therapeutic efficacy of rimantidine 218 1999
Chemotherapy for 227 1996
Efficacy of rimantadine 251 1997
INTERMITTENT HYPOXIC TRAINING (IHT)
Effect on performance in racehorses 304
ISOXSUPRINE
Physiological effects 195 1996
Pharmacologic effects 215 1995
Absence of response to oral dose 225 1998
Glucuronide by LC/MS/MS  260 2000
Detection by GC/MS 263
Detection by LC/MS/MS 266
KENTUCKY EQUINE DRUG RESEARCH PROGRAM
Drugs, horses, and the KEDRC 8 1976
Drugs, racehorses and the KEDRC 13 1976
Kentucky laboratory takes lead against horse dopers 257 1992
KAPPA-OPIOID RECEPTOR
As equine analgesic 110 1985
U-50,488H response 125 1988
LAMENESS
Electronic hoof tester 109 1985
LIDOCAINE
Pharmacological effects & analytical detection 228 1998
Identification by ELISA & MS/MS 261 2000
LIQUID CHROMATOGRAPHY/ MASS SPECTROSCOPY (LC/MS/MS)
Isoxsuprine-glucuronide 260 2000
Lidocaine identification 261 2000
Clenbuterol quantitation in serum 275 2001
Clenbuterol detection in serum 281 2000
Cocaine metabolite detection 282 2000
Guanabenz in serum 289 2003
LOCAL ANESTHETICS
Differential nociception effects 98 1985
Tranquilizers, analgesics and ... 168 1989
Pharmacology & pharmacokinetics 186 1995
Highest no-effect doses 189 1996
Anesthetic efficacy 190 1994
Lack of efficacy of sarapin 213 1997
LOCOMOTOR ACTIVITY
Fentanyl & apomorphine 38 1979
Selective blockade to narcotic analgesics 40 1978
Selective blockade to narcotic analgesics 46 1981
  Fentanyl & other narcotic analgesics 59 1979
Review: Behavioral models 73 1982
Enkephalins versus opiates 80 1982
Quantitation of medications 217 1996
Quantitation of locomotor effect 224 1997
Caffeine 235 2001
Amitraz, detomidine, acepromazine 250 1997
MANDELONITRILE
Toxicokinetics, relevance to MRLS 307
Pharmacokinetics, relevance to MRLS 309
MARE REPRODUCTIVE LOSS SYNDROME (MRLS)
ESI/MS fragmentation patterns of ergot alkaloids 296
Analytical detection of cyanide and thiocyanate in equine blood and serum 298
Stallion influence on reproductive loss during... 303
Ergot alkaloids screened by HPLC-electrospray[+] tandem quadrupole mass spectrometry 305
Spectrophotometric method for determination of cyanide 306 2003
Toxicokinetics of cyanide and mandelonitrile, relevance to MRLS 307
Overview and preliminary toxicological approaches 308
Pharmacokinetics of cyanide and mandelonitrile, relevance to MRLS 309
Proceedings, First Workshop on Mare Reproductive Loss Syndrome 311 2003
Cherry trees, plant cyanogens, caterpillars and MRLS 316 2003
Experimentally-induced late fetal loss 319 2003
Mouse model for 320 2003
Septic Penetrating Setal Emboli Hypothesis (copyright 6/17/03) 323
Ongoing toxicological/other investigation (presentation) 328
Toxicokinetic/mathematical analysis of MRLS 331
MRLS Workshop session summary: toxicological hypotheses 332 2003
MASS SPECTROMETRY
Fragmentation patterns of ergot alkaloids by electrospray tandem quadrupole mass spectrometry 296
Ergot alkaloids screened by HPLC-electrospray[+] tandem quadrupole mass spectrometry 305
MASS SPECTROSCOPY
Cocaine quanitification 194 1996
Lidocaine quanitification 228 1998
Mepivacaine quanitification 229 1999
Bupivacaine quanitification 234 1999
Isoxsuprine by MS/MS 266
Celecoxib detection 277 2000
MAZINDOL
ELISA detection 141 1988
ELISA detection 147 1988
MECLOFENAMIC ACID
Review: non-steroidal anti-inflammatory drugs 55 1979
MEDICATION CLASSIFICATION
ARCI classification guidelines 256 1998
HBPA Proposed National Policy on Drug Testing and Therapeutic Medication 330 2003
MEDICATION CONTROL
Proceedings, 3rd International Symposium on Equine Medication Control 66 1979
Reflections on positive results from medication control tests 77 1984
Rules 120 1986
Practitioners' strategies to avoid problems 174 1995
Overview, 1900 to date 232 1998
Consequence of sensitive testing 233 1997
HBPA Proposed National Policy on Drug Testing and Therapeutic Medication 330 2003
MEPERIDINE (DEMEROLョ)
Behavioral response (foot-step counts) 39 1979
Locomotor response 59 1979
MEPIVACAINE
Pharmacological effects & analytical detection 229 1999
Detection of 3-hydroxymepivacaine 237 1998
METABOLISM
Drug metabolism and elimination  49 1979
METABOLITES
Equine metabolites and standards 252 1998
Synthesis of clenbuterol metabolites 284 2000
METHADONE
Behavioral response (foot-step counts) 39 1979
Locomotor response 59 1979
METHAMPHETAMINE
Potentiation of fentanyl locomotor response 73 1982
METHOCARBAMOL
ELISA detection 220 1996
METHYLFENTANYLS
Pharmacology & detection methods 133 1989
PCFIA detection 136 1987
ELISA detection 140 1988
RIA & ELISA detection 148 1988
ELISA & RIA detection/ cross-reactivity 155 1989
METHYLPHENIDATE (RITALINョ)
Pharmacokinetics & behaviour (variable interval) 20 1981
Effect of furosemide on disposition 22 1978
Variable interval response 73 1982
METHYLXANTHINES
Pharmacokinetics and pharmacodynamics 211 1998
ELISA for caffeine 216 1996
MORPHINE
TLC method 36 1978
Behavioral response (foot-step counts) 39 1979
Locomotor response 59 1979
Quantitative detection (GC) 65 1981
Glucuronide enzyme hydrolysis 67 1982
Goldenseal interference in detection 72 1981
Pharmacokinetics & protein binding 76 1983
ELISA detection 138 1988
ELISA detection 149 1988
ELISA detection 173 1991
Na+K+-ATPASE
Ouabain & cassaine interaction 19 1977
Effects of monovalent cations 28 1979
Drug receptor theory/ opiate receptor 62 1980
NALBUPHINE (NUBAINョ)
Enzyme hydrolysis & TLC detection 70 1982
NALORPHINE
TLC method 36 1978
NALOXONE (NARCANョ)
Blockage of locomotor response 73 1982
Endotoxic & hemorrhagic shock 79 1984
Blockage of locomotor response 125 1988
NAPROXEN (EQUIPROXENョ)
Review: non-steroidal anti-inflammatory drugs 55 1979
NARCOTIC ANALGESICS
Detection & pharmacokinetics of pentazocine 27 1979
Pentazocine & fentanyl 31 1979
Opiate receptor 32 1978
Locomotor effects of fentanyl & pentazocine 38 1979
Behavioral response (foot-step counts) 39 1979
Quantitation & selected blockage 40 1978
Selective blockage of locomotor response 46 1981
Pharmacokinetics and behavior 59 1979
Morphine detection 65 1981
 -Opioid receptor narcotics 110 1985
Detection & pain measurements 127 1989
Effect on horses 170 1989
NITROGLYCERIN
EIPH and racing horses 196 1995
NOCICEPTION (PAIN PERCEPTION)
Control by medication 89 1983
Neurophysiology & equine models 90 1983
Phenylbutazone & cutaneous pain perception 91 1983
Phenylbutazone & local anesthetics 98 1985
Methods of study 104 1985
Effect of ethylketazocine 107 1986
Effect of U-50,488H  125 1988
Review: Narcotic analgesics 127 1989
Antinociception effect of amitraz 231 1998
NO-EFFECT LEVELS
Overview 287 2001
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
Effects of furosemide on plasma and urinary concentration 9 1976
Phenylbutazone review 16 1977
Effect of furosemide on disposition of phenylbutazone 22 1978
Phenylbutazone review 53 1979
Review: Naproxen, flunixin, meclofenamic acid 55 1979
Phenylbutazone in horses racing under controlled medication program 69 1981
Flunixin meglumine pharmacology 81 1982
Actions, effects & role of phenylbutazone 88 1983
Lack of effect of phenylbutazone on normal cutaneous pain perception 91 1983
Effect of urine pH on urine concentration of phenylbutazone 93 1983
Testimony on phenylbutazone testing 95 1983
Population distribution of phenylbutazone after oral and IV dosing 96 1984
Effect of phenylbutazone on nociception 98 1985
Population distribution of phenylbutazone and metabolites in plasma and urine 99 1985
Phenylbutazone & basic drug detection 101 1985
Plasma and serum concentrations of phenylbutazone 24 hours after dosing 102 1985
Review of phenylbutazone levels in post-race samples 103 1984
Review of phenylbutazone   105 1986
Phenylbutazone & acidic drug detection 108 1986
Phenylbutazone & acidic drug detection 116 1985
Influence of urinary pH on concentration of phenylbutazone 117 1985
Phenylbutazone & basic drug detection 118 1985
Detection of phenylbutazone by PCFIA 154 1989
Phenylbutazone & others 166 1989
ELISA assay for flunixin 219 1996
N-SUBSTITUTED  b-ALANINES
Michael addition synthesis 157 1989
OPERANT CONDITIONING AND VARIABLE INTERVAL TRAINING 
Quantitating method for centrally acting drugs 51 1982
Measure of behavior 58 1979
Review: Behavioral models 73 1982
Effects of acepromazine 78 1982
Duration of action of detomidine 132 1988
Applications to equine pharmacology 142 1989
OPIATE RECEPTOR
Narcotic analgesics 32 1978
Drug receptor theory and Na+K+-ATPase 62 1980
OPIATES/ OPIOIDS
Narcotic analgesics 32 1978
Status of drug receptor theory 62 1980
Enkephalins & locomotor activity 80 1982
 κ-Opioid receptor narcotics 110 1985
OSMOLALITY
Furosemide urines 285 2000
Comparison of specific gravity and osmolality in post-race urine 321
OUBAIN
Interaction with Na+K+-ATPase 19 1977
OXYGLOBINョ
Detection in equine plasma 300
OXYPHENBUTAZONE
Effects on phenylbutazone metabolism 6 1977
Effect of urine pH 87 1983
Effect of urine pH 93 1983
Population distribution 96 1984
Effects on basic drug TLC 101 1985
Plasma & serum concentrations 102 1985
Effects on acidic drug TLC 108 1986
Effects on acidic drug TLC 116 1985
Effects on basic drug TLC 118 1985
OXYMORPHONE (NUMORPHANョ)
Enzyme hydrolysis & TLC detection 70 1982
PAIN PERCEPTION (NOCICEPTION)
Control by medication 89 1983
Neurophysiology & equine models 90 1983
Phenylbutazone & cutaneous pain perception 91 1983
Phenylbutazone & local anesthetics 98 1985
Methods of study 104 1985
Effect of ethylketazocine 107 1986
Effect of U-50,488H  125 1988
Review: Narcotic analgesics 127 1989
Electro-acupuncture and pain threshold 273 1999
PARTICLE CONCENTRATION FLUORESCENCE IMMUNOASSAY (PCFIA)
Fentanyl & congeners 136 1987
Carfentanil 137 1987
Furosemide 143 1988
Acepromazine 144 1988
Human drugs of abuse 145 1988
Furosemide 146 1988
Cocaine 152 1989
Phenylbutazone 154 1989
Review of immunoassay drug tests 156 1989
PENICILLIN
Procaine-penicillin complex 4 1977
Chemotherapy in the horse 35 1978
PENILE PROLAPSE
Effects of acepromazine 74 1981
Effects of acepromazine 78 1982
PENTAZOCINE (TALWINョ)
Effects of furosemide on urinary concentration 18 1977
Effect of furosemide on disposition 22 1978
Detection, pharmacokinetics & clearance 27 1979
Detection, pharmacokinetics, clearance & behavior 31 1979
TLC method 36 1978
Behavioral response (foot-step counts) 39 1979
Locomotor response 59 1979
Enhancement of TLC detection 70 1982
PERFORMANCE
Medication of performance horses 57 1982
Drugs and the Performance Horse (book) 75 1981
Drugs and equine performance 86 1982
Drugs and racehorse performance 100 1985
Drugs and performance (book chapter) 128 1988
Effects of drugs on racehorse performance 159 1988
Effects of drugs on performance, use of ELISA tests 171 1989
PETROLEUM UNDERGROUND STORAGE TANKS
Standards corrective action for release 207 1995
pH (EQUINE URINE)
Effects on oxyphenbutazone concentrations 87 1983
Effects on phenylbutazone & metabolites 93 1983
Effects on phenylbutazone population distribution 99 1985
Effects on phenylbutazone & metabolites 117 1985
Population parameters & acidification methods 139 1990
Population parameters & acidification methods 151 1988
Distribution of post-race urine pH 199 1995
Standardbred/ Thoroughbred urine pH comparison 221 1996
PHENYL-tert-BUTYLNITRONE
Effect on endotoxin toxemia 205 1997
PHENOTHIAZINE TRANQUILIZERS
Pharmacology review 56 1979
Atypical conditions/ qualitative recovery 61 1981
Pharmacology & behavioral effects of acepromazine 74 1981
Pharmacokinetics & behavioral response of acepromazine 78 1982
Acepromazine ELISA & cross-reactivity 144 1988
ELISA detection of acepromazine 150 1988
Effects of acepromazine on spontaneous locomotor activity 250 1997
PHENYLBUTAZONE (BUTAZOLIDINョ)
Effect of furosemide on concentration 9 1976
Review 16 1977
Effect of furosemide on disposition 22 1978
Non-steroidal anti-inflammatory drugs 53 1979
Controlled medication program 69 1981
Actions, effects & role 88 1983
Normal cutaneous pain perception 91 1983
Effect of urine pH on concentration 93 1983
Testimony on drug testing 95 1983
Population distribution 96 1984
Differential effects on nociception 98 1985
Population distribution & urinary pH 99 1985
Effects on basic drug TLC 101 1985
Plasma & serum concentrations 102 1985
Review 105 1986
Effects on acidic drug TLC 108 1986
Effects on acidic drug TLC 116 1985
Influence of urinary pH on concentration 117 1985
Effects on basic drug TLC 118 1985
PCFIA & ELISA detection 154 1989
Non-isotopic immunoassays (review) 156 1989
Phenylbutazone & others 166 1989
PINE OIL
Toxicity, detection, residues & pathology 12 1976
POISONOUS PLANTS
Poisoning in horses 226 1997
POST-RACE TESTING
Evaluation of blood & urine testing 37 1979
Phenylbutazone levels 103 1984
Effect of unitary pH on phenylbutazone levels 117 1985
Application of immunoassay drug tests 156 1989
ELISA based immunoassay tests 161 1988
Testing for drugs in horses 167 1989
Distribution of post-race urine pH 199 1995
Standardbred/ Thoroughbred urine pH comparison 221 1996
Equine drug testing 206 1998
PRE-PURCHASE TESTING
Review 124 1986
Review 327
PRE-RACE TESTING
Evaluation of blood & urine testing 37 1979
Role in equine medication control 82 1983
Application of immunoassay drug tests 156 1989
Immunoassay based 160 1988
PROCAINE (NOVOCAINョ)
Recovery from biological fluids 1 1975
Pharmacology 2 1976
Procaine esterase properties 3 1976
Procaine-penicillin complex 4 1977
Pharmacokinetics & behavior 5 1977
Review 10 1976
Plasma & urinary concentrations 15 1977
Effect of furosemide on disposition 22 1978
Review 29 1978
Procaine residues in urine 130 1995
ELISA detection 182 1992
Highest no-effect dose 189 1996
Local anesthetic efficacy 190 1994
Significance in post-race urine 197 1996
Highest no-effect dose  247 1995
PROCAINE ESTERASE
In equine plasma & synovial fluid 3 1976
PROCAINE-PENICILLIN
Evidence against complex 4 1977
PROTEIN BINDING
Morphine in horses 76 1983
Acepromazine in horses 78 1982
PYRILAMINE
Identification and synthesis of metabolite 253
Detection and pharmacokinetics 272
Detection and disposition 276 2000
PYRANTEL TARTRATE
Clearance times & forensic significance 175 1991
Detection times 179 1992
QUALITY ASSURANCE
Procedures and quality assurance of TIP 264 1999
Administration samples & double-blind testing 283 2000
QUINIDINE
Effects on phenylbutazone metabolism 6 1977
RADIOIMMUNOASSAY (RIA)
Fentanyl detection (3H) 68 1981
Etorphine screening (3H) 112 1986
Etorphine screening (3H) 113 1985
Fentanyl screening (3H) 123 1986
Fentanyl screening (123I) 126 1986
Etorphine screening (123I) 131 1988
Carfentanil detection 137 1987
Fentanyl & derivatives detection 148 1988
Detomidine detection 153 1989
Fentanyl, alfentanil, sufentanil, carfentanil 155 1989
REGULATIONS OF RACING
ARCI violations and penalties 278 2000
HBPA Proposed National Policy on Drug Testing and Therapeutic Medication 330 2003
REMIFENTANIL
Detection by Fentanyl Group ELISA 283 2000
Detection 270 2000
Identification & detection of metabolite 280 2000
RESERPINE (SERPASILョ)
Effects on platelet uptake of serotonin 30 1979
Review 34 1978
Platelet serotonin uptake & behavior 42 1979
Biochemical & behavioral effects 43 1978
Variable interval conditioning response 58 1979
RIMANTADINE
Pharmacology & pharmacokinetics 218 1999
Overview of pharmacology, side effects 227 1996
Efficacy in equine influenza 251 1997
RISK MANAGEMENT
Release from petroleum storage tanks 207 1995
ROPIVACAINE
Pharmacological effects & analytical detection 236 2001
Detection of glucuronidide 255 2000
SARAPIN
Lack of local anesthetic efficacy 213 1997
SCIENTIFIC METHODS
Equine forensic science 262 1998
SELEGILINE
Detection in equine urine: Preliminary report 238
Detection, metabolism, behavioral effects 292
Detection of selegiline in amphetamine ELISA 312
SEROTONIN
Reserpine effects on platelet uptake 30 1979
Reserpine effects on platelet uptake 42 1979
SKIN TWITCH/ HOOF WITHDRAWAL LATENCY
Fentanyl 106 1985
Ethylketazocine 107 1986
U50,488H 125 1988
SPECIFIC GRAVITY
Furosemide urines 285 2000
STANOZOLOL
ELISA development 288 2000
STEROIDS
Anabolic steroid group 26 1978
Review of corticosteroids 45 1979
Pharmacology of corticosteroids 63 1980
Steroidal anti-inflammatory agents 163 1989
Anabolic steroids: use & excretion 169 1989
Corticosteroids: use & characterization 185 1993
Stanozolol ELISA 288 2000
STIMULANTS
Review: Actions of central stimulants 47 1979
Review: Actions of central stimulants 48 1979
How they affect horses 170 1989
STREPTOMYCIN
Pharmacology review 52 1979
SUFENTANIL (SUFENTAョ)
PCFIA detection 136 1987
ELISA detection 140 1988
RIA & ELISA detection 148 1988
ELISA & RIA detection 155 1989
SULFONOTOLTRAZURIL
EPM therapy 286 2001
TANKS, PETROLEUM UNDERGROUND STORAGE
Standards for corrective action for release 207 1995
TESTING INTEGRITY PROGRAM (TIP)
Furosemide seminar 259 2000
Equine forensic science 262 1998
Procedures and quality assurance 264
THERAPEUTIC AGENTS
Workshop Proceedings 200 1995
Fifties rules, nineties testing 202 1995
Workshop outcomes 223 1996
Quantitation of locomotor effect 224 1997
Analytical-pharmacological relationships 233 1997
Testing for therapeutic medications 243 1998
Testing for therapeutic medications 244 1999
HBPA Proposed National Policy on Drug Testing and Therapeutic Medication 330 2003
Overview of the effective world rules on therapeutic medications 335 2002
THIN LAYER CHROMATOGRAPHY (TLC)
Furosemide detection 23 1978
Overspray for phenolic alkaloid drugs 36 1978
Enzyme hydrolysis & drug detection 70 1982
Flunixin detection 81 1982
Clenbuterol detection 94 1983
Phenylbutazone & basic drug detection 101 1985
Phenylbutazone & acidic drug detection 108 1986
Phenylbutazone & acidic drug detection 116 1985
Phenylbutazone & basic drug detection 118 1985
Etorphine detection 122 1985
DADA detection 135 1988
Comparison to immunoassay screening methods 156 1989
THIOCYANATE
Analytical detection and "normal" population data 298
THRESHOLDS 
Hematocrit as indicator 172 1992
HNEDs for local anesthetics 189 1996
Workshop interim report 192 1994
Review of methodologies 193 1994
Plasma or urinary? 198 1994
Workshop Proceedings 200 1995
Fifties rules, nineties testing 202 1995
Regulatory threshold for cocaine 214 2000
Workshop outcomes 223 1996
Analytical-pharmacological relationships 233 1997
Testing for therapeutic medications 243 1998
Testing for therapeutic medications 244 1999
Use of force plate 279 2000
Overview of no-effect levels 287 2001
TOBACCO SMOKE EXPOSURE
Determined by cotinine ELISA 177 1993
Determined by t-3'-hydroxycotinine ELISA 183 1996
TOLTRAZURIL
Descriptive pharmacokinetics 230
Preliminary pharmacokinetics 249 1997
EPM therapy 286 2001
TOLTRAZURIL SULFONE
Identification, detection & pharmacokinetics 291
Sodium salt formulation 294
TOXICOLOGY
Toxicology (book chapter) 85 1983
Development of ELISA for t-3'-hydroxycotinine as biomarker for smoke exposure 183 1996
Spectrophotometric method for determination of cyanide 306 2003
Toxicokinetics of cyanide and mandelonitrile, relevance to MRLS 307
Cherry trees, plant cyanogens, caterpillars and MRLS 316 2003
MRLS: ongoing toxicological investigation 328
A toxicokinetic/mathematical model of MRLS 331
Session summary on toxicological hypotheses from MRLS Workshop 332 2003
TRANQUILIZERS
Pharmacology review: phenothiazines 56 1979
Local anesthetics, analgesics and ... 168 1989
U-50,488H ( κ-OPIOID)
Behavior, nociception & autonomic response 125 1988
URINARY pH
Effects on oxyphenbutazone concentrations 87 1983
Effects on phenylbutazone & metabolites 93 1983
Effects on phenylbutazone population distribution 99 1985
Effects on phenylbutazone & metabolites 117 1985
Population parameters & acidification methods 139 1990
Population parameters & acidification methods 151 1988
Distribution of post-race urine pH 199 1995
VACCINES
Equine Drugs and Vaccines (book) 191 1994
VARIABLE INTERVAL TRAINING AND OPERANT CONDITIONING
Quantitating method for centrally acting drugs 51 1982
Measure of behavior 58 1979
Review: Behavioral models 73 1982
Acepromazine response 78 1982
Duration of action of detomidine 132 1988
Applications to equine pharmacology 142 1989

Publications  (1975 to date)

PUBLICATIONS:

  1. Post RL, Kume S, Tobin T, Orcutt B, Sen AK:  Flexibility of an active centre in (Na++K+)-dependent ATPase.  J Gen Physiol 54(1)Part 2:306-326, 1969.

  2. Sen AK, Tobin T, Post RL:  A cycle for ouabain inhibition of the (Na++K+)-ATPase.  J Biol Chem 244:6596-6604, 1969.

  3. Tobin T, Banerjee SP, Sen AK:  Allosteric interactions in the (Na++K+)-ATPase.  Nature 225:745, 1970.

  4. Tobin T, Sen AK:  Stability and ligand sensitivity of  [3H]-ouabain binding to the (Na++K+)-ATPase.  Biochem Biophys Acta 198:120-131, 1970.

  5. Akera T, Hook JB, Tobin T, Brody TM:  Cardiac glycoside sensitivity of (Na++K+)-activated ATPase in newborn rats.  Res Commun Chem Pathol Pharmacol 4:599-706, 1972.

  6. Tobin, T, Baskin SI, Akera T, Brody TM:  Nucleotide specificity of the (Na++K+)-dependent adenosine triphosphatase.  Molec Pharmacol 8:256-263, 1972.

  7. Tobin T, Brody TM:  Rates of dissociation of enzyme-oubain complexes and K0.5 values in (Na++K+)-adenosine triphosphatase from different species.  Biochem Pharmacol 21:1553-1560, 1972.

  8. Tobin T, Henderson R, Sen AK:  Species and tissue differences in the rate of dissociation of ouabain from the (Na++K+)-ATPase.  Biochem Biophys Acta 274:551-555, 1972.

  9. Akera T, Baskin SI, Tobin T, Brody TM:  Ouabain: Temporal relationship between the ionotropic effect and the in vitro binding to and dissociation from (Na++K+)-activated ATPase.  Naunyn-Schmiedeberg's Archiv fur Pharmacol 277:151-162, 1973.

  10. Akera T, Rech RH, Marquis WJ, Tobin T, Brody TM:  Lack of relationship between brain (Na++K+)-activated adenosine triphosphatase and the development of tolerance to ethanol in rats.  J Pharmacol Exp Ther 185:594-601, 1973.

  11. Tobin T, Akera T, Baskin SI, Brody TM:  Calcium and sodium and potassium dependent adenosine triphosphatase: Its mechanism of inhibition and identification of the EI-P intermediate.  Mol Pharmacol 9:336-349, 1973.

  12. Tobin T, Akera T, Hogg RE, Brody TM:  Ouabain binding to sodium- and potassium-dependent triphosphatase: Inhibition by the b-y-methylene analogue of adenosine triphosphatase.  Mol Pharmacol 9:278-281, 1973.

  13. Tobin T, Akera T, Ku D, LU MC: Reversibility of the interaction of strophanthidin bromacetate with the cardiotonic steroid binding site of sodium- and potassium-dependent adenosine triphosphatase.  Mol Pharmacol 9:676-685, 1973.

  14. Tobin T, Dirdjosudiono S, Baskin SI:  Pharmacokinetics and distribution of diphenylhydantoin in kittens.  Am J Vet Res 34:951-954, 1973.

  15. Akera T, Baskin SI, Tobin T, Brody TM:  Cardiac glycosides: Temporal relationship between the inotropic action and binding to and dissociation from Na++K+-activated ATPase in vitro. Recent Advances in Studies on Cardiac Structure and Metabolism, Vol 4, Myocardial Biology (ed NS Dhalla), University Park Press, Baltimore , pp 139-147, 1974.

  16. Akera T, Baskin SI, Tobin T, Brody TM, Manian AA: 7-8-Dihydroxychlorpromazine:  (Na++K+)-ATPase inhibition and positive inotropic effect.  Advances in Biochem Psychopharmacol 9:633-640, 1974.

  17. Akera T, Brody TM, So RH-M, Tobin T, Baskin SI:  Factors and agents that influence cardiac glycoside Na++K+-ATPase interaction.  Ann NY Acad Sci 242:617-634, 1974.

  18. Akera T, Tobin T, Gatti A, Shieh I-S, Brody TM: Effect of potassium on the conformational state of the complex of ouabain with sodium- and potassium-dependent adenosine triphosphatase.  Mol Pharmacol 10:509-518, 1974.

  19. Ku D, Akera T, Tobin T, Brody TM:  Effects of rubidium on cardiac tissue, Inhibition of Na ++K+-ATPase and stimulation of contractile force.  Res Commun Chem Pathol Pharmacol 9: 431-440, 1974.

  20. Tobin T, Akera T, Baskin SI, Brody TM:  The mechanism of the Ca++ ion inhibition of sodium-potassium ATPase.  Recent Advances in Studies on Cardiac Structure and Metabolism.  Vol. 4, Myocardial Biology (ed NS Dhalla), University Park Press, Baltimore , pp 139-147, 1974.

  21. Tobin T, Akera T, Brody TM:  Studies on the two phosphoenzyme conformations of Na++K+-ATPase.  Ann NY Acad Sci 242: 120-132, 1974.

  22. Tobin T, Akera T, Dworin JZ, Brody TM:  Fluoride nephropathy: Lack of direct involvement of renal ATPase.  Canad J Physiol Pharmacol 52:489-495, 1974.

  23. Tobin T, Akera T, Han CS, Brody TM:  Lithium and rubidium interactions with sodium- and potassium-dependent adenosine triphosphatase: A molecular basis for the pharmacological actions of these ions.  Mol Pharmacol 10:501-508, 1974.

  24. Tobin T, Akera T, Lee CY, Brody TM:  Ouabain binding to (Na++K+)ATPase: Effects of nucleotide analogues and ethacrynic acid.  Biochem Biophys Acta 354:102-117, 1974.

  25. Tobin T, Tai Cy, Arnett S:  Recovery of procaine from biological fluids.  Res Commun Chem Path Pharmacol, 11(2):187-194, 1975.

  26. Abramson HN, Huang CL, Wu TF, Tobin T:  Thiocardenolides. I.  Synthesis and biological actions of 3- -thiocyanato-14 -hydroxy-5- -card-20(22)-endide.  J Pharm Sci 65:765-768, 1975.

  27. Ku D, Akera T, Tobin T, Brody TM:  Effects of monovalent cations of cardiac Na++K+-ATPase activity and on contractile form.  Naunyn-Schmiedeberg's Archiv fur Pharmacol 20: 113-131, 1975.

  28. Tobin T, Abramson H:  Irreversible inhibition of [3H]-ouabain binding to Na++K+-ATPase by digoxigenin-3-12 di-bromacetate, an alkylating derivative of digoxigenin.  Eur J Pharmacol 32: 243-250, 1975.

  29. Tobin T, Akera T:  Shodowmycin, a nucleotide site directed inhibitor of Na++K+-ATPase.  Biochem Biophys Acta 389: 126-136, 1975.

  30. Tobin T, Akera T, Brody SI, Brody TM:  The mechanism of interaction of cassaine with Na++K+-ATPase.  Biochemical Soc Transactions 2:1375-1378, 1975.

  31. Tobin T, Akera T, Brody TM:  Gel electrophoretic identity of the Na+, Mg++, and Na+Ca++-stimulated phosphorylations of Na+K+-ATPase.  Biochem Biophys Acta 393, 117-125, 1975.

  32. Tobin T, Akera T, Brody TM, Tanaja HA:  Irreversible inhibition of Na++K+-ATPase: Strophanthidin 3,5-bisparabenzoylbenzoate, a photo-chemical analog of strophanthidin.  Res Commun Chem Pathol Pharmacol 10: 605-617, 1975.

  33. Akera T, Ku D, Tobin T, Brody TM:  The complexes of ouabain with sodium- and potassium-activated adenosine triphosphatase formed with various ligands: The relationship to the complex formed in the beating heart.  Mol Pharmacol 12:101-114, 1976.

  34. Tobin T, Blake JW, Tai Cy, Arnett S:  The pharmacology of procaine in the horse. I. A preliminary report.  Am J Vet Res, 37:1107-1110, 1976.

  35. Blake JW, Tobin T:  The gas-liquid chromatograph and the electron capture detector in equine drug testing.  Brit J Sports Med, 10:129-132, 1976.

  36. Han CS, Tobin T, Akera T and Brody TM:  Effects of alkali metal  cations on phospho-enzyme levels and  [3H]-ouabain binding to Na++K+-ATPase.  Biochem Biophys Acta 429:993-1005, 1976.

  37. Ku D, Akera T, Tobin T, Brody TM:  Comparative species studies on the effects of monovalent cations and ouabain on cardiac Na++K+-ATPase and contractile force.  J Pharm Exp Therap 197(2):458-469, 1976.

  38. Miller JR, Blake JW, Tobin T:  Electron capture detection of an apomorphine-heptafluorobutyrate derivative at low picogram levels.  Res Commun Chem Path Pharmacol, 15(3):447-455, 1976.

  39. Roberts BL, Blake JW, Tobin T:  Drug interactions in the horse: Effect of furosemide on plasma and urinary levels of phenylbutazone.  Res Commun Chem Path Pharmacol, 15:257-265, 1976.

  40. Tobin T:  Drugs, Horses and the Kentucky Equine Drug Research Program.  Proc 2nd Conv Natn'l Assoc. State Racing Commissioners, San Diego, CA, 1976, pp 89-99.

  41. Tobin T:  Drugs, Racehorses and the Kentucky Drug Research Program. The Blood-Horse, Vol CII(14):1453-1455, April 1976.

  42. Tobin T, Akera T, Brody SI, Ku D, Brody TM:  Cassaine: Mechanism of inhibition of Na++K+-ATPase and relationships of this inhibition to cardiotonic actions.  Eur J Pharmacol 32: 133-145, 1976.

  43. Tobin T, Akera T, Han CS, Brody TM:  Studies on the stable inhibition of Na++K+-ATPase by cassaine.  Eur J Pharmacol 35: 59-68, 1976.

  44. Tobin T, Akera T, Taneja HA, Brody TM:  Cardiotonic site directed irreversible inhibition of Na++K+-ATPase by 3-azidoacetyl-strophanthidin, a photochemical analogue of strophanthidin.  Eur J Pharmacol 35:68-76, 1976.

  45. Tobin T, Blake JW: A review of the pharmacology, pharmacokinetics and behavioral effects of procaine in the Thoroughbred Horse.  Brit J Sports Med, 10:109-116, 1976.

  46. Tobin T, Swerczek TW, Blake JW:  Pine-oil toxicity in the horse: Drug detection, residues and pathological changes.  Res Commun Chem Path Pharmacol 15:291-301, 1976.

  47. Tobin T, Blake JW, Tai Cy, Sturma L, Arnett S:  The pharmacology of procaine in the horse II. The procaine esterase properties of equine plasma and synovial fluid.  Am J Vet Res, 37:1165-1170, 1976.

  48. Tobin T, Tai Cy, O'Leary J, Sturma L, Arnett S:  The pharmacology of procaine in the horse. III. Evidence against the existence of a procaine-penicillin complex.  Am J Vet Res, 38:437-442, 1977.

  49. Gabel AA, Tobin T, Ray RS, Maylin GA :  Furosemide (Lasixョ) in horses: A review.  J Eq Med Surg, 1:215-218, 1977.

  50. Gabel AA, Tobin T, Ray RS, Maylin GA :  Phenylbutazone (ButazolidinR) in horses: A review.  J Eq Med Surg, 1:221-225, 1977.

  51. Miller MR, Roberts BL, Blake JW, Valentine RW, Tobin T:  Drug interactions in the horse. III. Effects of furosemide on urinary concentrations of glucuronide metabolites of pentazocine.  Res Commun Chem Path Pharmacol, 17;447-456, 1977.

  52. Tobin T:  Furosemide (Lasixョ) in the horse: An overview.  Proc 23rd Annual Conv AAEP, Vancouver , 1977, pp 419-421.

  53. Tobin T, Akera T:  Interaction of ouabain and cassaine with Na++K+-ATPase and its relationship to their inotropic actions.  In: Drug Action at the Molecular Level, MacMillan Pub Co, London , 1977, pp 213-133.

  54. Tobin T, Blake JW:  The pharmacology of procaine in the horse V. Relationships between plasma and urinary concentrations of procaine.  J Eq Med Surg, 1:188-194, 1977.

  55. Tobin T, Blake JW, Maylin G:  Use of bumetanide in horses.  Am J Vet Res, 38:413, 1977.

  56. Tobin T, Blake JW, Sturma L, Arnett S, Truelove J:  The pharmacology of procaine in the horse: Pharmacokinetics and behavioral effects.  Am J Vet Res, 38:637-647, 1977.

  57. Tobin T, Blake JW, Valentine R:  Drug interactions in the horse. I. Effects of chloramphenicol, quinidine and oxyphenbutazone on phenylbutazone metabolism.  Am J Vet Res, 38:123-127, 1977.

  58. Ballard S. White CB, Woods WE, Voos J, Tobin T:  Biochemical and behavioral effects of reserpine in the horse.  Presented at the 2nd Equine Pharmacology Symposium, Ohio State University , Columbus , OH , 1978.

  59. Blake JW, Tobin T, Roberts BL:  A modified Folin-Denis over-spray for the detection of phenolic alkaloidal drugs.  Irish Vet J, pp 209-213, December 1978.

  60. Combie J, Dougherty J, Shults T, Tobin T:  Quantitation and selective blockade of response to narcotic analgesics in the horse.  2nd Equine Pharmacology Symposium, The Ohio State University , Columbus pp 183-188, 1978.

  61. Roberts BL, Blake JW, Tobin T:  The pharmacology of furosemide in the horse. II. Its detection, pharmacokinetics and clearance from urine.  J Eq Med Surg, 2:185-194, 1978.

  62. Shults T, Roberts BL, Blake JW, Tobin T:  The detection, identification and basic pharmacology of furosemide in the horse.  2nd Equine Pharmacology Symposium, the Ohio State University , Columbus , pp 43-57, 1978.

  63. Tobin T:  A review of the pharmacology of furosemide in the horse.  Proc 3rd Int値 Equine Doping Conference, Rome , March 1977.  Atti Della Conferenza Int値 Sul Doping, pp 323-352, 1978.

  64. Tobin T: A review of the pharmacology of procaine in the horse.  J Eq Med Surg, 2:209, 213-214, 1978.

  65. Tobin T:  A review of the pharmacology of reserpine in the horse.  J Eq Med Surg, 2(10):433-438, 1978.

  66. Tobin T: Chemotherapy in the horse: The penicillins.  J Eq Med Surg, 2(11):475-479, 1978.

  67. Tobin T: Narcotic analgesics and the opiate receptor in the horse.  J Eq Med Surg, 2:397-399, 1978.

  68. Tobin T:  Pharmacology Review: A review of recent research on furosemide in the horse.  J Eq Med Surg, 2:314, 320-321, 1978.

  69. Tobin T: Pharmacology Review: Testing for drugs in horses.  J Eq Med Surg, 2(12):518-524, 1978.

  70. Tobin T: Plasma and urinary drug concentrations, drug "clearance times", and pharmacological effects.  J Eq Med Surg, 2(6):262-267, 1978.

  71. Tobin T: The anabolic steroid androgen group of drugs.  J Eq Med Surg, 2:163-165, 1978.

  72. Tobin T, Roberts BL, Miller RW:  The pharmacology of furosemide in the horse. I. Effects on the disposition of procaine, methylphenidate, phenylbutazone and pentazocine.  J Eq Med Surg, 1:402-409, 1978.

  73. Tobin T, Roberts BL, Swerczek TW, Crisman M:  The pharmacology of furosemide in the horse. III, Dose and time response relationships, effects of repeated dosing, and performance effects.  J Eq Med Surg, 2:216-226, 1978.

  74. Akera T, Gubitz RH, Brody TM, Tobin T:  Effects of monovalent cations on Na++K+-ATPase in rat brain slices.  Europ J Pharmacol, 55:281-292, 1979.

  75. Combie J, Dougherty J, Nugent E, Tobin T:  The pharmacology of narcotic analgesics in the   horse. IV. Dose and time response relationships for behavioral responses to morphine, meperidine, pentazocine, anileridine, methadone, and hydromorphone.  J Eq Med Surg, 3:377-385, 1979.

  76. Combie J, Shults T, Tobin T:  The pharmacokinetics and behavioral effects of fentanyl and other narcotic analgesics in the horse.  Proc 3rd Int値 Symposium on Equine Medication Control, Lexington , June 1979, pp 311-321.

  77. Maylin, Fregin, Tobin et al.:  Drugs and performance testing in racing horses.  Report of NASRC Veterinary Chemists Advisory Committee, March 27, 1979 .  NASRC Proceedings, San Francisco, 85-106, 1979.

  78. Shults T, Combie J, Dougherty J, Tobin T:  Variable interval conditioning in the horse: A sensitive measure of behavior.  Proc 3rd Int値 Symposium on Equine Medication Control, Lexington , June 1979, pp 367-379.

  79. Tobin T:  Pharmacology Review: Streptomycin, gentamicin, and the amino-glycoside antibiotics.  J Eq Med Surg, 2:206-212, 1979.

  80. Tobin T:  Pharmacology Review: The corticosteroids.  J Eq Med Surg, 3:10-15, 1979.

  81. Tobin T: Pharmacology Review: The non-steroidal anti-inflammatory drugs. I. Phenylbutazone. J Eq Med Surg, 3:253-258, 1979.

  82. Tobin T:  Pharmacology Review: The non-steroidal anti-inflammatory drugs. II. Equiproxin, meclofenamic acid, flunixin and others.  J Eq Med Surg, 3(7):298-392, 1979.

  83. Tobin T, Ballard S:  Pharmacology Review: The phenothiazine "tranquilizers."  J Eq Med Surg, 3:460-466, 1979.

  84. Tobin T, Blake JW, Woods WE (eds):  Proceedings of the 3rd Int値 Symposium on Equine Medication Control, Lexington , KY 1979.

  85. Tobin T, Combie J, Miller JR, Crisman MW, Blake JW:  The pharmacology of narcotic analgesics in the horse. II. Studies on the detection, pharmacokinetics, urinary clearance times and behavioral effects of pentazocine and fentanyl in the horse.  Irish Vet J, 33:169-176, 1979.

  86. Tobin T, Combie J, Shults T:  Pharmacology Review: Actions of central stimulant drugs in the horse. II. J Eq Med Surg, 3(3):102-109, 1979.

  87. Tobin T, Combie J, Shults T, Dougherty J:  The pharmacology of narcotic analgesics in the horse. III. Characteristics of the locomotor effects of fentanyl and apomorphine.  J Eq Med Surg, 3(6):284-288, 1979.

  88. Tobin T, Maylin GA , Henion J, Woodward C, Ray RS, Johnston J, Blake JW:  An evaluation of pre- and post-race testing and blood and urine drug testing in horses.  J Eq Med Surg, 3(2):85-90, 1979.

  89. Tobin T, Miller JR:  The pharmacology of narcotic analgesics in the horse. I. The detection, pharmacokinetics and urinary "clearance times" of pentazocine.  J Eq Med Surg, 3(4):191-198, 1979.

  90. Tobin T, White CB, Woods WE:  The pharmacology of reserpine in the horse. II. Effects of reserpine on platelet serotonin uptake and behavior.  J Eq Med Surg, 3:446-451, 1979.

  91. Tobin T, Woods WE:  Pharmacology review: Actions of central stimulant drugs in the horse. I. J Eq Med Surg, 3(2):60-66, 1979.

  92. Tobin T, Woods WE:  Pharmacology Review: Drug metabolism and elimination in the horse.  J Eq Med Surg, 3(3):150-156, 1979.

  93. White CB, Woods WE, Tobin T: The pharmacology of reserpine in the horse. I. Effects of reserpine and imipramine on platelet uptake of serotonin, in vitro and in vivo.  J Eq Med Surg 3(7):325-330, 1979.

  94. Tobin T:  An overview of the major antibiotics in equine medicine.  Proc 26th Annual Conf AAEP, Anaheim , CA , December 1980, pp 491-502.

  95. Tobin T, Combie J:  The pharmacology and therapeutics of exercise-induced pulmonary hemorrhage (EIPH).  Proc 26th Annual Conf AAEP, Anaheim , CA , December 1980, pp 435-440.

  96. Tobin T, Combie JD, Akera T:  Current status of drug receptor theory with specific reference to Na++K+-ATPase and opiate receptors.  Proc 2nd Symposium on Veterinary Pharmacology and Therapeutics, Philadelphia , June 1980, pp 123-165.

  97. Tobin T, Nugent T:  Pharmacology of corticosteroid therapy in the horse.  Proc 26th Annual Conf AAEP, Anaheim , CA , December 1980, pp 411-415.

  98. Ballard S, Tobin T:  Atypical conditions for qualitative recovery of acepromazine and chlorpromazine from plasma.  J Toxic & Environmntl Hlth, 7:745-751, 1981.

  99. Ballard S, Tobin T:  Pharmacology, pharmacokinetics, and behavioral effects of acepromazine in the horse.  Proc 4th Int値 Conf Control Drugs in Racehorses, Melbourne , Australia , May 1981, pp 81-86.

  100. Ballard S, Tobin T:  Recovery of acepromazine from equine plasma and its pharmacology in the horse.  Proc 4th Int値 Symposium on Equine Medication Control, 1981.

  101. Combie J, Blake JW, Ramey BE, Tobin T:  The pharmacology of narcotic analgesics in the horse: Quantitative detection of morphine in equine blood and urine and logit-log transformations of this data.  Am J Vet Res 42(9):1523-1530, 1981.

  102. Combie J, Blake JW, Tobin T:  Phenylbutazone and other drugs in horses racing under a controlled medication program.  Proc 4th Int値 Symposium on Equine Medication Control, Melbourne , Australia , May 1981, pp 68-73.

  103. Combie J, Nugent T, Tobin T:  Inability of goldenseal to interfere with the detection of morphine in urine.  J Equine Vet Sci, 2(1):16-19, 1981.

  104. Combie J, Nugent T, Tobin T:  The pharmacology of furosemide in the horse. IV. The duration of reduction of urinary concentration of drugs.  J Equine Vet Sci, 1:203-207, 1981.

  105. Combie J, Shults T, Nugent E, Dougherty J, Tobin T:  Pharmacology of narcotic analgesics in the horse.  Selective blockade of narcotic-induces locomotor activity.  Am J Vet Res 42:716-721, 1981.

  106. Shults T, Kownacki AP, Woods WE, Valentine RW, Dougherty J, Tobin T:  Pharmacokinetics and behavioral effects of methylphenidate in Thoroughbred horses.  Am J Vet Res, 42: 722-726, 1981.

  107. Tobin T:  Drugs and the Performance Horse.  Charles C. Thomas, Springfield , IL , 1981.

  108. Ballard S, Shults, T, Kownacki AA, Blake JW, Tobin T:  The pharmacokinetics, pharmacological responses, and behavioral effects of acepromazine in the horse.  J Vet Pharmacol Therap, 5:21-31, 1982.

  109. Chay S, Woods WE, Nugent TE, Blake JW, Tobin T:  The pharmacology of non-steroidal anti-inflammatory drugs in the horse.  III. Flunixin meglumine (Banamineョ).  Equine Practice, 4(10):16-23, 1982.

  110. Combie J, Blake JW, Nugent T, Tobin T:  Furosemide, Patella vulgata  b-glucuronidase and drug analysis: Conditions for enhancement of the TLC detection of apomorphine, butorphanol, hydromorphone, nalbuphine, oxymorphone and pentazocine in equine urine.  Res Comm in Chem Pathol Pharmacol 35(1):27-41, 1982.

  111. Combie J, Blake JW, Nugent T, Tobin T:  Morphine-glucuronide hydrolysis: Superiority of glucuronidase from Patella vulgata.  Clin Chem, 28(1):83-86, 1982.

  112. Nugent TE, Combie J, Weld JM, Burns P, Tobin T:  Effects of enkephalins versus opiates on locomotor activity of the horse.  Res Commun Chem Path Pharmacol, 35(3):405-419, 1982.

  113. Shults T, Combie J, Dougherty J, Tobin T:  Variable-interval responding in the horse: A sensitive method of quantitating effects of centrally acting drugs.  Am J Vet Res, 43(7):1143-1146, 1982.

  114. Tobin T:  Medication of performance horses.  In: Equine Medicine and Surgery, Am Vet Pub, Inc, Santa Barbara , CA , 1982, pp 158-172.

  115. Tobin T, Combie J:  Performance testing in the horse: A review of the role of simple behavioral models in the design of performance experiments.  J Vet Pharmacol Therap, 5:105-118, 1982.

  116. Tobin T, Combie J, Nugent T:  Drug "clearance times" and "detection times" in horses: A reappraisal.  J Vet Pharmacol Therap, 5:195-197, 1982.

  117. Tobin T, Kamerling S, Nugent TE:  Drugs and equine performance: A review.  In Snow DH, Persson SGB, Rose RJ (eds): Equine Exercise Physiology, Proc 1st Int値 Conf, Oxford , UK , 1982, pp 510-520.

  118. Chay S, Woods WE, Rowse K, Nugent T, Blake JW, Tobin T:  The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration.  J Drug Metab Disp, 11(3):226-231, 1983.

  119. Chay S, Woods WE, Tobin T:  The pharmacokinetics and blood levels of furosemide after intravenous administration.  Proc 5th Int値 Conf, Cont use of drugs in race horses, Toronto , Canada , June 1983, pp 41-49.

  120. Collett L, Kamerling S, Woods WE, Weckman T, Nugent T, DeQuick D, Tobin T:  Clearance times and behavioral effects of clenbuterol in the horse.  Proc 5th Int値 Conf, Cont use of drugs in race horses, Toronto , Canada , June 1983, pp 265-271.

  121. Combie J, Nugent T, Tobin T:  Pharmacokinetics and protein binding of morphine in horses.  Am J Vet Res, 44(5):870-874, 1983.

  122. DeQuick D, Chay S, Kamerling S, Tobin T:  Pain perception in the horse and its control by medication: An overview.  Proc 5th Int値 Conf, Cont use of drugs in race horses, Toronto, Canada, June 1983, pp 50-51.

  123. Greene EW, Woods WE, Tobin T:  Pharmacology, pharmacokinetics, and behavioral effects of caffeine in horse.  Am J Vet Res, 44(1):57-63, 1983.

  124. Houston T, Tobin T, Blake JW:  Effect of urine pH on urine levels of oxyphenbutazone in racing horses.  J Drug Metab Dist, 11(6):617-619, 1983.

  125. Houston T, Tobin T, Blake JW:  Effect of urine pH on urine levels of phenylbutazone, oxyphenbutazone and g-hydroxyphenylbutazone in racing horses.  Proc 5th Int値 Conf, Cont use of drugs in race horses, Toronto, Canada, June 1983, pp 26-33.

  126. Kamerling S, DeQuick D, Crisman M, Weckman T, Nugent T, Tobin T:  Phenylbutazone: Lack of effect on normal cutaneous pain perception in the horse.  Proc 5th Int値 Conf, Cont use of drugs in race horses, Toronto, Canada, June 1983, pp 85-89.

  127. Kamerling S, Tobin T:  Pain: Neurophysiology and experimental equine models.  Proc 5th Int値 Conf, Cont use of drugs in race horses, Toronto, Canada, June 1983, pp 52-55.

  128. Oehme FW, Tobin T (eds):  Toxicology.  Chapter 13 in Robinson NE (ed), Current Therapy in Equine Medicine.  Sanders, Philadelphia, 1983, pp 573-615.

  129. Tobin T:  Phenylbutazone: Its actions, effects, and role in equine medicine.  Modern Equine Practice, Jan/Feb 1983, p 25.

  130. Tobin T:  Pre-race testing and its role in equine medication control.  Equine Vet J, 15(1):54-55, 1983.

  131. Tobin T:  Testimony on phenylbutazone and furosemide testing before the house subcommittee on criminal justice.  The Horsemen's Journal, 34(7):142-149, 1983.

  132. Chay S, Woods WE, Nugent T, Weckman T, Houston T, Sprinkle F, Blake JW, Tobin T, Soma L, Yocum J, Smith JD:  Population distributions of phenylbutazone and oxyphenbutazone after oral and IV dosing in horses.  J Vet Phar Therap, 7:265-276, 1984.

  133. Houston T, Chay S, Woods WE, Blake JW, Tobin T:  Phenylbutazone levels in post-race samples from horses racing in Kentucky: A review.  Proc 4th Symposium on Veterinary Pharmacology and Therapeutics, College Station TX, April 1984, pp 96-115.

  134. Tobin T, Combie J:  Some reflections on positive results from medication control tests in the USA.  Eq Vet J, 16:43-46, 1984.

  135. Weld JM, Kamerling S, Combie J, Nugent TE, Woods WE, Oeltgen P, Tobin T:  The effects of naloxone on endotoxic and hemorrhagic shock in horses.  Res Commun Chem Path Pharmacol, 44(2):227-238, 1984.

  136. Blake JW, Tobin T, Chang S-L:  TLC detection of etorphine in equine urines.  Crone DL (ed) Proc 6th Int値 Conf Racing Analysts and Vets, Hong Kong, 1985, pp 205-208.

  137. Houston T, Chay S, Woods WE, Combs G, Kamerling S, Blake JW, Edmunson AG, Vessiney R, Tobin T:  Phenylbutazone and its metabolites in plasma and urine of Thoroughbred horses racing in California and Kentucky: Population distributions and the effects of urinary pH.  J Vet Pharm Therap, 8:136-149,1985.

  138. Kamerling SG, DeQuick DJ, Weckman TJ, Sprinkle FP, Tobin T:  Differential effects of phenylbutazone and local anesthetics on nociception in the equine.  Eur J Pharm, 107:35-41, 1985.

  139. Kamerling S, DeQuick DJ, Weckman TJ, Tobin T:  Dose-related effects of fentanyl on autonomic and behavioral responses in performance horses.  Gen Pharmacol, 16(3):253-258, 1985.

  140. Kamerling S, Weckman TJ, DeQuick D, Tobin T:  A method for studying cutaneous pain perception and analgesia in horses.  J Pharm Meth, 13(3):267-274, 1985.

  141. Kamerling SG, Weckman TJ, Donahoe J, Tobin T:  The effects of kappa-opioid receptor narcotics in the horse: A new class of equine analgesics.  Crone DL (ed) Proc 6th Int値 Conf Racing Analysts Vets. Hong Kong, 1985, pp 37-45.

  142. Karns PA, Kamerling SG, Bagwell CA, Tobin T:  Quantification of equine hoof lameness using an electronic hoof tester.  Crone DL (ed) Proc 6th Int値 Conf Racing Analysts Vets. Hong Kong, 1985, pp 325-329.

  143. Soma LR, Sams R, Duer W, Tobin T, Woodward C, McDonald J: Plasma and serum concentrations of phenylbutazone and oxyphenbutazone in racing Thoroughbreds 24 hours after various dosage regimens.  Am J Vet Res, 46(4):932-938, 1985.

  144. Tobin T, Kamerling SG, Anderson RL:  Drugs and race-horse performance.  Trends in Pharm Sci, 6(3):129-132, 1985.

  145. Tobin T, Woods WE, Anderson RC, Houston T, Blake JW:  Influence of urinary pH on concentrations of phenylbutazone and its metabolites in post-race urine samples.  Crone DL (Ed) Proc 6th Int値 Conf Racing Analysts and Vets. Hong Kong, 1985, pp 59-68.

  146. Tobin T, Woods WE, Blake JW:  Efficacy and cost of testing for illegal medications in horses.  Crone DL (Ed) Proc 6th Int値 Conf Racing Analysts and Vets. Hong Kong, 1985, pp 113-121.

  147. Tobin T, Woods WE, Weckman TJ, Wood TW, Chang S-L, Blake JW: Radioimmunoassay screening for etorphine in racing horses.  Crone DL (ed) Proc 6th Int値 Conf Racing Analysts Vets., Hong Kong, 1985, pp 199-203.

  148. Woods WE, Blake JW, Tobin T:  Effects of phenylbutazone and oxyphenbutazone on basic drug detection in high performance thin layer chromatographic systems.  Crone DL (ed) Proc 6th Int値 Conf Racing Analysts and Vets. Hong Kong, 1985, pp 83-88.

  149. Woods WE, Chay S, Houston T, Blake JW, Tobin T:  Effects of phenylbutazone and oxyphenbutazone on basic drug detection in high performance thin layer chromatographic systems.  J Vet Pharm Therap, 8:181-189, 1985.

  150. Woods WE, Chay S, Houston T, Blake JW, Tobin T:  Efficacy of testing for illegal medication in horses: A survey.  JAVMA, 187:927-930, 1985.

  151. Woods WE, Weckman TJ, Blake JW, Tobin T:  Effects of phenylbutazone and oxyphenbutazone on acidic drug detection in high performance thin layer chromatographic systems.  Crone DL (ed) Proc 6th Int値 Conf Racing Analysts and Vets. Hong Kong, 1985, pp 69-82.

  152. Blake JW and Tobin T: Testing for drugs in horses. J Eq Vet Sci, 6(2):93-97, 1986.

  153. Kamerling SG, DeQuick DJ, Weckman TJ, Tobin T:  Dose-related effects of ethylketazocine on nociception, behavior, and autonomic responses in the horse.  J Pharm Pharmacol, 38(1):40-45, 1986.

  154. Tobin T:  Experiences as an expert witness: Educating people while under oath.  J Eq Vet Sci, 6(3):129-133, 1986.

  155. Tobin T:  Medication Control: Rules.  J Eq Vet Sci 6(4):191-195, 1986.

  156. Tobin T:  Medication Control: The efficacy and cost of drug testing.  J Eq Vet Sci 6(6):333-336, 1986.

  157. Tobin T:  Medication Control: Uncertainty in the "Detection Times" for drugs in horses.  J Eq Vet Sci 6(3):124-128, 1986.

  158. Tobin T, Blake JW:  Pre-purchase testing for drugs in horses: A review.  J Eq Vet Sci, 6(1):35-39, 1986.

  159. Tobin T, Chay S, Kamerling S, Woods WE, Weckman TJ, Blake JW, Lees P:  Phenylbutazone in the horse: A review.  J Vet Pharmacol Therap, 9:1-25, 1986.

  160. Tobin T, Woods WE, Tai H-H, Tai C, Weckman TJ, Wood TW, Blake JW:  Radioimmunoassay screening for fentanyl in equine and human urine samples with an iodinated fentanyl analog.  Proc 40th Meeting Assoc of Racing Chem, Lexington, KY, 141-150, 1986.

  161. Woods WE, Chay S, Blake JW, Tobin T:  Effects of phenylbutazone on acidic drug detection on high performance thin layer chromatographic systems.  J Pharmacol Meth, 16(4):297-313, 1986.

  162. Woods WE, Tai HH, Tai C, Weckman TJ, Wood TW, Barrios H, Blake JW, Tobin T:  High-sensitivity radioimmunoassay screening method for fentanyl.  Am J Vet Res 47(10):2180-2183, 1986.

  163. Woods WE, Weckman TJ, Wood TW, Chang S-L, Blake JW, Tobin T: Radioimmunoassay screening for etorphine in racing horses.  Res Commun Chem Path Pharmacol, 52(2):237-249, 1986.

  164. McDonald J, Gall R, Wiedenback P, Bass VD, DeLeon B, Brockus C, Stobert D, Wie S, Prange CA, Yang JM, Tai CL, Weckman TJ, Woods WE, Tai H-H, Blake JW, Tobin T:  Immunoassay detection of drugs in horses. I. Particle concentration fluoroimmunoassay detection of fentanyl and its congeners.  Res Commun Chem Path Pharmacol, 57(3):389-407, 1987.

  165. Weckman TJ, Tai C, Woods WE, Tai H-H, Blake JW, Tobin T:  A review of the pharmacology and detection of fentanyl and its congeners in the horse.  Proc 41st Meeting Assoc of Racing Chem., 1987, Los Angeles, CA, pp287-313.

  166. Yang J-M, Tai CL, Weckman TJ, Tai H-H, Blake JW, Tobin T, McDonald J, Gall R,   Wiedenback P, Bass VD, Brockus C, Stobert D, Wie S, Prange CA:  Immunoassay detection of drugs in horses. II. Detection of carfentanil in equine urine by RIA, PCFIA and ELISA.         Res Commun Subst Abuse, 8(2):59-75, 1987.

  167. Kamerling S, Weckman TJ, Tobin T:  Dose related effects of kappa agonist U-50,488H on behavior, nociception and autonomic response in the horse. Eq Vet J, 20(2):114-118,1988.

  168. Kwiatkowski S, Sturma L, Dai MR, Tai H-H, Watt DS, Tai CL, Woods WE, Weckman TJ, Yang J-M, Wood TW, Chang S-L, Blake JW, Tobin T, Prange C, Brockus C, Stobert D, Wie, Chung RA, McDonald J, Bass VD, Merchant S, Artemenko M: Immunoassay detection of drugs in racing horses. VII. Detection of acepromazine in equine blood and urine by ELISA and PCFIA.  Res Comm Chem Path Pharmacol, 61(3):391-412, 1988.

  169. McDonald J, Gall R, Wiedenback P, Bass VD, DeLeon B, Brockus C, Stobert D, Wie S, Prange CA, Ozog FJ, Green MT, Woods WE, Tai CL, Dai MR, Weckman TJ, Tai H-H, Yang J-M, Chang S-L, Blake JW, Tobin T:  Immunoassay detection of drugs in horses.  III. Detection of morphine in equine blood by a one step ELISA assay.  Res Commun Chem Path Pharmacol, 59(2):259-278, 1988.

  170. McDonald J, Watt DS, Kwiatkowski S, Tai H-H, Wie S, Prange CA, Wood T, Tobin T: Immunoassay based pre-race testing:  An effective pre-race testing system. In: Breccia A (ed), Il Controllo Antidoping dei Cavalli da Corsa (Proc Int値 Seminar Tech Pharmacol Legal Aspects Antidoping Control Racehorses).  Bologna, Italy, October, 1988, pp 43-52 (145-157).

  171. Prange CA, Brockus C, Stobert D, Wie S, McDonald J, Gall R, Wiedenbach P, Bass  VD, DeLeon B, Ozog FJ, Green MT, Woods WE, Tai CL, Dai MR, Weckman TJ, Tai H-H, Yang J-M, Chang S-L, Blake JW, Tobin T:  Immunoassay detection of drugs in racing horses. V. Detection of mazindol in equine blood and urine by a one step ELISA assay.  Res Comm Subst Abuse, 9(1):13-30, 1988. 

  172. Prange CA, Wie S, Brockus CL, Dahl, PA, Lewis EL, Brecht JM, Conner JC, Chung RA, McDonald J, Bass VD, Merchant S, Kwiatkowski S, Woods WE, Watt DS, Tai H-H, Blake JW, Chang S-L, Tobin T: Screening for human drugs of abuse by particle concentration fluorescence immunoassay (PCFIA).  Res Comm Subst Abuse, 9(3,4):129-155, 1988.

  173. Sturma L, Tai H-H, Tai CL, Tobin T, McDonald J, Wie S, Prange CA, Ozog FJ:  ELISA detection of morphine in the horse.  Proc 7th Int値 Confer Racing Analysts Vets, Louisville, KY, April 1988, 145-153.

  174. Tai CL, Wang C-J, Weckman TJ, Popot MA, Woods WE, Yang J-M, Blake JW, Tai H-H, Tobin T:  Radioimmunoassay for etorphine in horses with a 125I analog of etorphine.  Am J Vet Res, 49(5):622-628, 1988.

  175. Tobin T, Galley RH:  Drugs and performance.  Chapter 11 in Jones WE (ed), Equine Sports Medicine.  Lea and Febiger, Philadelphia, 1988, pp 189-204.

  176. Tobin T, McDonald J, Ozog FJ, Prange CA:  Enzyme linked immunosorbent assay (ELISA): A revolution in equine drug testing.  Equine Veterinary Data, 9(2):19-31, 1988.

  177. Tobin T, Stanley SD, Kwiatkowski S, Watt DS, Tai H-H, McDonald J, Prange CA:  ELISA based immunoassay tests in post-race testing. In: Breccia A (ed), Il Controllo Antidoping dei Cavalli da Corsa (Proc Int'l Seminar Tech Pharmacol Legal Aspects Antidoping Control Racehorses). Bologna, Italy, October, 1988, pp 85-104 (163-184).

  178. Tobin T, Tai H-H, Tai CL, Houtz PK, Dai MR, Woods WE, Weckman TJ, Yang J-M, Chang S-L, Blake JW, McDonald J, Gall R, Wiedenbach P, Bass VD, DeLeon B, Ozog FJ, Green MT, Brockus C, Stobert D, Wie S, Prange CA:  Immunoassay detection of drugs in horses. IV. Detection of fentanyl in equine blood and urine by a one step ELISA assay.  Res Comm Chem Path Pharmacol, 60(1):97-115, 1988.

  179. Tobin T, Watt DS, Kwiatkowski S, Tai H-H, Blake JW, McDonald J, Kalita S, Prange CA, Wie S:  Non-isotopic immunoassay drug tests in racing horses: A review of their application to pre-and post-race testing, drug quantitation, and human drug testing.  Res Comm Chem Path Pharm, 62(3):371-395, 1988.

  180. Tobin T, Wood T:  The effects of drugs on race horse performance. Proc 34th Convent Am Assoc. Equine Pract, San Diego, CA, Dec, 1988, pp 639-650.

  181. Weckman TJ, Tobin T, Tai H-H, Yang J-M, Wie S, Prange CA, Ozog FJ:  ELISA and RIA detection of fentanyl in the horse.  Proc 7th Int値 Confer Racing Analysts Vets, Louisville, KY, April 1988, 123-133.

  182. Wood T, Tai CL, Henry P, Woods WE, Tobin T, Wie S, Prange CA, McDonald J, Ozog FJ, Green MT:  The detection of furosemide in equine blood by fluorescence and enzyme-linked immunoassays.  Proc 7th Int値 Confer Racing Analysts Vets, Louisville, KY, April 1988, 113-122.

  183. Wood TW, Weckman TJ, Woods WE, Tobin T, Dougherty J:  Detomidine: A preliminary analysis of its duration of action in the horse by variable interval responding.  Eq Vet J, 20(5):320-322, 1988.

  184. Wood T, Weckman TJ, Henry P, Chang S-L, Blake JW, Tobin T: Parameters of equine urine pH and methods of acidification.  Proc 7th Int値 Confer Racing Analysts Vets, Louisville, KY, April 1988, 259-265.

  185. Woods WE, Wang C-J, Houtz PK, Tai H-H, Wood TW, Weckman TJ, Yang J-M, Chang S-L, Blake JW, Tobin T, McDonald J, Kalita S, Bass VD, Weege P, DeLeon B, Brockus C, Wie S, Chung RA, Brecht J, Conner J, Dahl P, Lewis E, Prange CA, Ozog FJ, Green M: Immunoassay detection of drugs in racing horses. VI.  Detection of furosemide (Lasixョ) equine blood by a one step ELISA and PCFIA.  Res Comm Chem Path Pharmacol, 61(1): 111-128, 1988.

  186. Yang J-M, Tobin T, Dai M-R, Watt D, Kwiatkowski S, Tai H-H, Sturma L, Wie S, Prange CA, McDonald J, Ozog FJ:  ELISA detection of acepromazine in the horse.  Proc 7th Int値 Confer Racing Analysts Vets, Louisville, KY, April 1988, 155-160.

  187. Yang J-M, Woods WE, Weckman TJ, Wood TW, Chang S-L, Blake JW, Tobin T:  The pharmacology, pharmacokinetics, and behavioral effects of diisopropylamine dichloroacetate (DADA) in the horse: A preliminary report.  Gen Pharmacol, 19(5):683-688, 1988.

  188. Blake JW, Woods WE, Goodman JP, Tobin T:  Pre- and post-race testing for drugs in racing horses. Equine Pharmacology and Therapy: Proc Eleventh Bain/Fallon Memorial Lectures, presented by Australian Equine Vet Assoc., Coffs Harbor, Australia, pp.  115-124, 1989.

  189. Kamerling S, Wood TW, DeQuick D, Weckman TJ, Tai C, Blake JW, Tobin T: Narcotic analgesics, their detection and pain measurement in the horse: A review. Eq Vet J, 21(1):4-12, 1989.

  190. Kwiatkowski S, Goodman JP, Stanley SD, Yang J-M, Wood T, Sturma L, Woods WE, Tian Z-G, Bertram S, Tai H-H, Weckman TJ, Chang S-L, Blake JW, Watt DS, Tobin T, McDonald J, Wie S, Chung RA, Brecht JM, Conner JC, Dahl PA, Lewis EL, Prange CA: Immunoassay detection of drugs in racing horses. X. Detection of phenylbutazone in equine blood and urine by particle concentration fluoroimmunoassay. Res Comm Subst Abuse, 10(2):123-139, 1989.

  191. Kwiatkowski S, Tobin T, Watt DS:  A synthesis of N-substituted -alanines: Michael addition of amines to trimethylsilylacrylate.  Synthesis, 946-949, 1989.

  192. Prange CA, Brockus C, Wie S, Chung RA, Brecht JM, Conner JC, Dahl PA, Lewis EL, McDonald J, Kalita S, Kwiatkowski S, Goodman JP, Sturma L, Stanley SD, Yang J-M, Wood T, Henry P, Weckman TJ, Woods WE, Watt DS, Tai H-H, Chang S-L, Blake JW, Tobin T:  Immunoassay detection of drugs in racing horses.  VIII. Detection of cocaine in equine blood and urine by particle concentration fluorescence immunoassay.  Res Comm Subst Abuse, 10(1):1-14, 1989.

  193. Stanley S, Tobin T, Wood T:  The effects of steroids in racing horses.  Pacemaker Update International, 2: 48, 1989.

  194. Tobin T:  Non-steroidal anti-inflammatory drugs: Phenylbutazone and others. Equine Pharmacology and Therapy: Proc Eleventh Bain/Fallon Memorial Lectures, presented by Australian Equine Vet Assoc., Coffs Harbor, Australia, , pp. 13-21, 1989.

  195. Tobin T:  The effects of drugs on equine performance and the use of ELISA tests in equine medication control. [Presented at Cong Wrld Equine Vet Assoc. (Equitana), Essen, West Germany, 1989.]  J Eq Vet Sci, 9 (3): 160-168, 1989.

  196. Tobin T:  Tranquilizers, analgesics and local anesthetics.  Equine Pharmacology and Therapy: Proc Eleventh Bain/Fallon Memorial Lectures, presented by Australian Equine Vet Assoc., Coffs Harbor, Australia, pp. 179-187, 1989.

  197. Tobin T, Kwiatkowski S, Watt DS, Tai H-H, Tai CL, Woods WE, Goodman JP, Taylor DG, Weckman TJ, Yang J-M, Tai JD, Stanley SD, Wood T, Chang S-L, Blake JW, McDonald J, Wie S, Prange CA, Uboh CE:  Immunoassay detection of drugs in biological samples:  XI. ELISA and RIA detection of fentanyl, alfentanil, sufentanil and carfentanil in equine blood and urine.  Res Comm Chem Pathol Pharmacol, 63(1):129-152, 1989.

  198. Tobin T, Stanley SD:  Anabolic steroids: use and excretion data. Equine Pharmacology and Therapy: Proc Eleventh Bain/Fallon Memorial Lectures, presented by Australian Equine Vet Assoc., Coffs Harbor, Australia, pp. 150-157, 1989.

  199. Tobin T, Wood T:  Passing the test: Immunoassay tests proving fast, reliable in detecting equine drugging.  Horseman and Fair World, 9, 52-54, 1989.

  200. Tobin T, Woods WE:  Detection times and clearance times for drugs in racing horses. Equine Pharmacology and Therapy: Proc Eleventh Bain/Fallon Memorial Lectures, presented by Australian Equine Vet Assoc., Coffs Harbor, Australia, pp.  105-113, 1989.

  201. Tobin T, Woods WE: Medication for exercise-induced pulmonary hemorrhage and its effects on other medications.  Equine Pharmacology and Therapy: Proc Eleventh Bain/Fallon Memorial Lectures, presented by Australian Equine Vet Assoc., Coffs Harbor, Australia, pp. 134-141, 1989.

  202. Tobin T, Woods WE:  Narcotics and stimulants: how they affect horses. Equine Pharmacology and Therapy: Proc Eleventh Bain/Fallon Memorial Lectures, presented by Australian Equine Vet Assoc., Coffs Harbor, Australia, pp. 49-59,1989.

  203. Tobin T, Woods WE:  Steroidal anti-inflammatory agents and adrenocorticotropic hormone.  Equine Pharmacology and Therapy: Proc Eleventh Bain/Fallon Memorial Lectures, presented by Australian Equine Vet Assoc., Coffs Harbor, Australia, pp.  23-30, 1989.

  204. Weckman TJ, Woods WE, Wood TW, Tai C, Tai H-H, Blake JW, Tobin T:  Pharmacologic effects and detection methods of methylated analogs of fentanyl in horses.  Am J Vet Res, 50(4):502-507, 1989.

  205. Wood T, Stanley SD, Tobin T:  Operant conditioning and its applications in equine pharmacology.  J Equine Vet Sci, 9(3): 124-130, 1989.

  206. Wood T, Tai CL, Taylor DG, Woods WE, Wang C-J, Houtz PK, Tai H-H, Weckman TJ, Yang J-M, Sturma L, Chang S-L, Goodman JP, Stanley SD, Blake JW, Watt DS, Tobin T, McDonald J, Wie S, Chung RA, Brecht JM, Conner JC, Dahl PA, Lewis EL, Prange CA: Immunoassay detection of drugs in racing horses. IX. Detection of detomidine in equine blood and urine by radioimmunoassay.  Res Comm Chem Path Pharm, 63(2):263-279, 1989.

  207. Frank M, Weckman TJ, Wood TW, Woods WE, Tai C, Chang S-L, Ewing A, Blake JW, Tobin T:  Hordenine: Pharmacology, pharmacokinetics and behavioural effects in the horse. Eq Vet J, 22(6):437-441, 1990.

  208. Jeganathan A, Park S, Kwiatowski S, Yang J, Stanley S, Woods WE, Tobin T, Tai H-H, Blake JW, Watt D:  The development of a generic fentanyl ELISA test.  Proc 43rd Meeting Assoc. Official Racing Chem, 87, 1990.

  209. Stanley S, Tai C, Goodman J, Taylor D, Wood T, Woods WE, Yang JM, Kwiatowski S, Tai H-H, Blake JW, Henry P, Chang S-L, Tobin T:  Immunoassay detection of drugs in racing horses.  Detection of reserpine in equine blood and urine by a one step ELISA.  Submitted to Fun App Tox, 1990.

  210. Tobin T, Blake JW, Potter M, Wood TW (eds):  Proc 7th Int値 Conf Racing Analysts Vets, Lexington, KY, 516 pages, 1990.

  211. Tobin T, Wood T:  ELISA testing in race horses.  Proc. Unione Nazionale L'Incremento Delle Razze Equine.  Rome Italy, 1990.

  212. Wood TW, Weckman TJ, Henry PA, Chang S-L, Blake JW, Tobin T: Equine urine pH: Normal population distribution and methods of acidification.  Eq Vet J, 22(2):118-121, 1990.

  213. Stanley SD, Jeganathan A, Wood TW, Henry PA, Turner S, Woods WE, Green MT, Tai H-H, Watt DS, Blake JW, Tobin T:  Morphine and etorphine:  Detection by ELISA in equine urine.  J Analytical Tox, 15(6):305-310, 1991.

  214. Stanley SD, Woods WE, Elliott D, Chen P-L, Ravard A, Tai H-H, Watt DS, Gerken DF, Sams RA, Tobin T:  Immunoassay detection of drugs in racing horses.  XIX. Detection of benzoylecgonine/cocaine in equine urine by ELISA.  Proc 44th Meeting Assoc. Official Racing Chem, Cincinnati, OH, pp. 218-228, 1991.

  215. Tobin T:  Detection times and clearance times for drugs in racing horses.  (Lecture Presentation, Paper from Bain Fallon Lectures)  Proceedings of the 76th Annual Convention of the Oklahoma Veterinary Medical Association, pp. 31-37, 1991.

  216. Tobin T:  Medication for exercised-induced pulmonary haemorrhage and its effects on other medications.  (Lecture Presentation, Paper from Bain Fallon Lectures)  Proceedings of the 76th Annual Convention of the Oklahoma Veterinary Medical Association, pp. 43-47, 1991.

  217. Tobin T:  Narcotics and stimulants: How they affect horses.  (Lecture Presentation, Paper from Bain Fallon Lectures)  Proceedings of the 76th Annual Convention of the Oklahoma Veterinary Medical Association, pp. 25-31, 1991.

  218. Tobin T:  Non-steroidal anti-inflammatory drugs: Phenylbutazone and others.  (Lecture Presentation, Paper from Bain Fallon Lectures)  Proceedings of the 76th Annual Convention of the Oklahoma Veterinary Medical Association, pp. 13-19, 1991.

  219. Tobin T:  Pre- and post-race testing for drugs in racing horses.  (Lecture Presentation, Paper from Bain Fallon Lectures)  Proceedings of the 76th Annual Convention of the Oklahoma Veterinary Medical Association, pp. 37-43, 1991.

  220. Tobin T:  Steroidal anti-inflammatory agents and adrenocorticotropic hormone.  (Lecture Presentation, Paper from Bain Fallon Lectures)  Proceedings of the 76th Annual Convention of the Oklahoma Veterinary Medical Association, pp. 19-25, 1991.

  221. Tobin T:  Tranquilizers, analgesics and local anaesthetics.  (Lecture Presentation, Paper from Bain Fallon Lectures)  Proceedings of the 76th Annual Convention of the Oklahoma Veterinary Medical Association, pp. 47-59, 1991.

  222. Wood T, Terhune T, Dunigan C, Goodman JP, Turner S, Blake JW, Stanley SD, Tobin T:  Clearance times and the forensic significance of the dietary anthelmintic pyrantel tartrate in performance horses.  J Eq Vet Sci., 11(4):220-224, 1991.

  223. Roth L, Harbison RD, James RC, Tobin T, Roberts SM. Cocaine hepatotoxicity: influence of hepatic enzyme inducing and inhibiting agents on the site of necrosis. Hepatology. 15(5):934-40, 1992.

  224. Smith JD, Arthur R, Barton J, Bowen E, Byars D, Derksen F, Erickson H, Gowen B, Hinchcliff KW, Manohar M, O'Callaghan M, Pascoe J, Robinson E, Sams RA, Soma LR, Sweeney C, Tobin T:  Exercise-induced pulmonary hemorrhage findings, Proc of Workshop, Part I.  Equine Pract, 14(1):19-25, 1992.

  225. Smith JD, Arthur R, Barton J, Bowen E, Byars D, Derksen F, Erickson H, Gowen B, Hinchcliff KW, Manohar M, O'Callaghan M, Pascoe J, Robinson E, Sams RA, Soma LR, Sweeney C, Tobin T:  Exercise-induced pulmonary hemorrhage findings, Proc of Workshop, Part II.  Equine Pract, 14(2):9-15, 1992.

  226. Smith JD, Arthur R, Barton J, Bowen E, Byars D, Derkson F, Erickson H, Gowen B, Hinchcliff KW, Manohar M, O'Callaghan M, Pascoe J, Robinson E, Sams RA, Soma LR, Sweeney C, Tobin T:  Exercise-induced pulmonary hemorrhage findings, Proc of Workshop, Part III.  Equine Pract, 14(3):28-31, 1992.

  227. Stanley SD, Dressler R, Woods WE, Langemeier J, Goodman JP, Pyrek J, Wood TW, Tobin T: The dietary anthelmintic pyrantel tartrate: An analysis of its detection times in geldings, mares and stallions.  Short CR (ed) Proc 9th Int値 Conf Racing Analysts Vets, New Orleans, LA, 1992, pp 321-326.

  228. Stanley SD, Yang J-M, Wood TW, Selonen JS, Watt DS, Tai H-H, Tobin T:  Detomidine clearance in the horse as determined by ELISA.  Short CR (ed) Proc 9th Int値 Conf Racing Analysts Vets, New Orleans, LA, 1992, pp 193-201.

  229. Stanley S, Yang J, Wood T, Yusufji A, Watt D, Tai H-H, Tobin T:  ELISA testing: Backgrounds in equine urine, test sensitivity, sample pooling and significance of number of tests.  Proc 45th Meeting Assoc Official Racing Chem 308-326, 1992.

  230. Stoilov I, Watt S, Cynkowska G, Goodman JP, (Tobin T), St Pyrek J:  Development of a mass spectral confirmation scheme for the carboxylic acid metabolites of detomidine and medetomidine in horse urine.  Submitted to Analytical Toxicology, 1992.

  231. Tobin T:  Kentucky Laboratory takes lead against horse dopers.  Clin Chem News, 18, pages 1-11, 1992.

  232. Wood TW, Stanley SD, Woods WE, Henry PA, Watt DS, Tobin T: Evaluation of threshold doses of drug action in the horse using hematocrit values as an indicator.  Res. Comm. Chem. Path. Pharmacol, 75(2):231-241, 1992.

  233. Woods, WE, Stanley DS, Yang J-M, Cook D, Gerkin DF, Detra RL, Sams RA, Jeganathan A, Watt DS, Tai H-H, Tobin T:  ELISA detection of azaperone in the racehorse.  Short CR (ed) Proc 9th Int値 Conf Racing Analysts Vets, New Orleans, LA, 1992, pp 187-192.

  234. Yang J-M, Stanley DS, Woods WE, Cook D, Hirsch R, Wood TW, Sams RA, Tai H-H, Watt DS, Tobin T:  Development of an ELISA for procaine in racing horses and dogs. Short CR (ed) Proc 9th Int値 Conf Racing Analysts Vets, New Orleans, LA, 1992, pp 377-384.

  235. Harkins JD, Carney JM, Tobin T:  Clinical use and characteristics of the corticosteroids.  Hinchcliff KW, Sams RA (eds), Vet Clin N Amer:  Equine Practice, Drug Use in Performance Horses, Vol 9, Saunders, Philadelphia, 1993, pp 543-562.

  236. Stanley SD, Gairola CG, Diana JN, Huffman M, Sadove RC, Woods WE, Kwiatkowski S, Tai H-H, Tobin T: Development and characterization of an ELISA for cotinine in biological fluids.  Inhalation Toxicology, 5(4): 403-413, 1993.

  237. Harkins JD, Mundy GD, Woods WE, Rees WA, Thompson KN, Tobin T:  Determination of the local anesthetic efficacy of procaine, cocaine, bupivacaine and benzocaine.  Proc 10th Int値 Conf Racing Analysts Vets, Stockholm, Sweden, p. 303-306, 1994.

  238. Queiroz-Neto A, Tobin T: Interpreta鈬o resultados positivos para cocana e cafena em amostras de cavalos de corrida.  Revista Brasileira de Toxicologia, 7(1/2) p. 5-10, 1994.  [KY Ag Exp Sta #95-14-056]

  239. Kellon EM, (in consultation with) Tobin T:  Equine Drugs and Vaccines:  A Guide for Owners and Trainers.  Breakthrough Press, Ossining, NY, 1994, 336 pp.

  240. Stanley S, Wood T, Goodman JP, Henry PA, Woods, WE, Chang S-L, Tai H-H, Watt D, Kwiatkowski S, Blake JW, Tobin T:  Immunoassay detection of drugs in racing horses:  Detection of ethacrynic acid and bumetanide in equine urine by ELISA.  J Analytical Tox, 18: 95-100, 1994.

  241. Tobin T:  Interim report on the workshop:  Testing for Therapeutic Medications, Environmental and Dietary Substances in Racing Horses, Univ of Kentucky, Lexington, KY, 1994.

  242. Hall NC, Yang J-M, Stanley SD, Mundy GD, Kryscio R, Tai H-H, Blake JW, Woods WE, Tobin T: Number of negative tests required to exclude specific levels of agent abuse in equine forensic chemistry.  Submitted to Equine Practice, 1995.

  243. Harkins JD, Stanley SD, Mundy GD, Carney JM, Sams RA, Woods WE, Tobin T:  A  review of the Pharmacology, pharmacokinetics, and regulatory control in the US of local anesthetics in the horse.  J Vet Pharmacol Therap, 18: pp 397-406, 1995.

  244. Harkins JD, Tobin T:  A review of the methodologies used to determine the highest no-effect doses (HNEDs) for medications in horses.  Proc Testing Therap Med Environ Diet Subst Racing Horses, Lexington, KY, 1995, pp 169-174.

  245. Harkins JD, Tobin T:  Racing horses, nitroglycerin and exercise-induced pulmonary hemorrhage.  Equine Vet J, 27(4):240-241, 1995.

  246. Sendlein LVA, Birge WJ, Blomquist GC, Dinger JS, Huffsey RR, Horstman SW, Kercher MD, McGinley P, Short DC, Struttman T, Taylor L, Tobin T, Dunn D, Naugle BI:  Final summary report:  Identification of appropriate standards for corrective action for a release from petroleum underground storage tanks.  Submitted to Petroleum Underground Storage Tank Environmental Assurance Fund Commission, 1995.

  247. Rees WA, Chambers TM, Fenger CK, Harkins JD, Blouin RA, Holland RE, Tobin T:  Pharmacokinetics and bioavailability of amantadine in the horse.  Proc 41st Convent Am Assoc. Equine Pract, Lexington, KY, 1995, pp270-271.

  248. Harkins JD, Mundy GD, Stanley SD, Woods We, Rees WA, Thompson KN, Tobin T:  Determination of highest no-effect doses (HNEDs) for local anesthetic responses to procaine, cocaine, bupivacaine, and benzocaine in Thoroughbred mares.  Proc 41st Convent Am Assoc. Equine Pract, Lexington, KY 1995, pp163-165.

  249. Stanley SD, Sams RA, Harkins JD, Mundy GD, Boyles J, Woods WE, Tobin T:  Frequency distribution of post-race urine pH from thoroughbreds and standardbreds:  Research and regulatory significance.  Equine Vet J, 27:471-473, 1995.

  250. Tobin T:  Fifties rules, nineties testing:  The need for thresholds for therapeutic medications.  Racing Update, 18 (10):89-92, 1995.

  251. Tobin T, Harkins JD:  Thresholds for high potency drugs:  Plasma or urinary thresholds?  Proc Testing Therap Med Environ Diet Subst Racing Horses, Lexington, KY, 1995, pp 185-189.

  252. Tobin T, Harkins JD, Woods WE, Hall NC, Queiroz-Neto A, Stanley SD, Mundy GD:  Testing for drugs, medications and other substances in racing horses.  Proc for the Short Course: Recent Advances in Equine Nutrition, Kentucky Equine Research, Inc., Versailles, KY, 1995, pp 1-26.  [KY Ag Exp Sta #95-14-057]

  253. Harkins JD, Stanley S, Mundy GD, Sams RA, Woods, WE, Rees WA, Thompson K, and Tobin T:  Determination of Highest No-Effect Doses (HNEDs) for local anesthetics.  Proc 41st Convent Am Assoc. Equine Pract, pp 163-165, 1995.

  254. Harkins JD, Stanley S, Mundy GD, Sams RA, Woods WE, Arthur R, Boyles J, and Tobin T:  Significance of Procaine residues in post race urine samples.  Proc 41st Convent Am Assoc. Equine Pract, pp 168-169, 1995.

  255. Harkins JD, Stanley S, Mundy GD, Sams RA, Woods WE, Richardson DR, and Tobin T:  Character and duration of pharmacological effect of isoxsuprine.  Proc 41st Convent Am Assoc. Equine Pract, pp 166-167, 1995.

  256. Tobin T, Mundy GD, Stanley SD, Sams RA, Crone D (eds): Testing for Therapeutic Medications, Environmental and Dietary Substances in Racing Horses, Proceedings of Workshop, Lexington, KY, 220 pages, 1995.  [KY Ag Exp Sta #95-14-058]

  257. Sams RA, Gerkin, DF, Detra RL, Wood WE, Stanley SD, Tobin T, Yang J-M, Tai H-H, Jegananthan A, Watt DS:  Identification of metabolites of azaperone in horse urine, J Pharm Sci. 85 pp 79-84, 1996.

  258. Stanley DS, Mundy GD, Woods WE, Harkins JD, Rees WA, Boyles J, Sams RA, Tobin T:  ELISA detection of cocaine and cocaine metabolites in equine urine, saliva and serum.  Manuscript in progress, 1996.

  259. Harkins JD, Mundy GD, Stanley SD, Woods WE, Rees WA, Thompson KN, Tobin T:  Determination of highest no-effect doses (HNEDs)for the local anesthetic responses to procaine, cocaine, bupivacaine and benzocaine.  Equine Vet J, 28:30-37, 1996.

  260. Harkins JD, Mundy GD, Stanley SD, Woods WE, Sams RA, Richardson DR, Tobin T:  Character and duration of pharmacologic effects of intravenous isoxsuprine.  Equine Vet J, 28(4):320-326, 1996.

  261. Harkins JD, Mundy GD, Stanley SD, Woods WE, Boyles J, Arthur RA, Sams RA, and Tobin T:  Regulatory significance of procaine residue in plasma and urine samples:  Preliminary communication, Equine Vet J, 28(2), 121-125, 1996.

  262. Edgar T, Tobin T, Watt D, Tai H-H, Schroedter D, Ice JT, Bass S: ELISA assay for caffeine. Proc 11th Intl'n Conf Racing Analysts Vets, Brisbane, Australia, 1996, pp 478-480.

  263. Harkins JD, Queiroz-Neto A, West D, Mundy GD, Tobin T: Quantitation of the locomotor effect of therapeutic medication in a behavior chamber.  Proc 11th Intl'n Conf Racing Analysts Vets, Brisbane, Australia, 1996, pp 117-120.

  264. Edgar T, Tobin T, Tai H-H, Bass S, Ice JT, Schroedter D: ELISA assay for flunixin. Proc 11th Int値 Conf Racing Analysts Vets, Brisbane, Australia, 1996, pp 466-469.

  265. Edgar T, Tobin T, Tai H-H, Bass S, Ice JT, Schroedter D: ELISA assay for methocarbamol. Proc 11th Int値 Conf Racing Analysts Vets, Brisbane, Australia, 1996, pp.459-462.

  266. Stanley SD, Troppmann A, Carter W, Sams RA, Harkins JD, Mundy GD, Boyles J, Woods WE, Tobin T: Frequency distributions of pH values in post-race urine samples from Standardbred and Thoroughbred horses. Proc 11th Int値 Conf  Racing Analysts Vets, Brisbane, Australia, 1996, pp 442-444.

  267. Foster CN, Boyles J, Crone DL, Mundy GD, Sams RA, Stanley SD, Tobin T: Response to a survey among international racing authorities on therapeutic medications, environmental and dietary substances in racehorses. Proc 11th Int値 Conf Racing Analysts Vets, Brisbane, Australia,1996, pp 46-55.

  268. Rees WA, Harkins JD, Woods WE, Blouin RA, Lu M, Fenger C, Holland RE, Tobin T, Chambers TM: Chemotherapy for equine influenza: Overview of the pharmacology and side effects of amantadine and rimantadine in the horse.  Proc 11th Int値 Conf Racing Analysts Vets, Brisbane, Australia, 1996, pp 355-357.

  269. Rees WA, Kwiatkowski S, Stanley SD, Granstrom DE, Yang J-M, Gairola CG, Drake D, Glowczyk J, Woods WE, Tobin T: The development and characterization of an ELISA for trans-3'-hydroxycotinine, a biomarker for mainstream and sidestream smoke exposure. Bengston DA, Henshel DS (eds), Environmental Toxicology and Risk Assessment: Biomarkers and Risk Assessment (5th Vol), Am Soc Testing Materials, Philadelphia, 1996, pp 149-162. [KY Ag Exp Sta #92-4-167]

  270. Woods WE, Mundy GD, Stanley SD, Sams RA, Harkins JD, Carter W, Boyles J, Rees WA, Bass S, Tobin T:  Detection and quantification of cocaine and its metabolites in equine body fluids after administration by different routes.  Proc 11th Int値 Conf Racing Analysts Vets, Brisbane, Australia, 1996, pp 503-507. [KY Ag Exp Sta # 96-14-080]

  271. Harkins JD, and Tobin T:  The pharmacologic effects of isoxsuprine.  Pferdeheilkunde, 12: 428-430, 1996.

  272. Harkins JD, Smith RA, Tobin T: Poisonous plants and feed related poisoning in horses. The Veterinarian痴 Practical Reference to Equine Nutrition, 135-165, 1997.

  273. Harkins JD, Tobin T, Mundy GD, Harrison L, Poonacha KB:  Exercise-induced pulmonary hemorrhage:  A Review of the etiology and pathogenesis.  Equine Pract., 19 (1):  22-28, 1997. [KY Ag Exp Sta # 95-14-182]

  274. Rees WA, Harkins JD, Woods WE, Blouin RA, Chambers T, Carter WG, Holland R, Fenger C, Tobin T: Amantadine and equine influenza:  Pharmacology, pharmacokinetics and neurological effects in the horse. Equine Vet J, 29(2): 104-110, 1997. [KY Ag Exp Sta #95-14-134]

  275. Harkins JD, Mundy GD, Stanley SD, Sams RA, Tobin T: Lack of  local anesthetic efficacy of Sarapin in an abaxial sesamoid block model. J Vet Pharmacol Therap 20, 229-232, 1997.

  276. Sleeman JM, Carter WG, Tobin T, Ramsay EC; Immobilization of domestic goats (Captra hircus) using orally administered carfentanil citrate and detomidine HCL.  J Zoo Wildlife Med, 28 (2):  158-165, 1997.

  277. Harkins JD, Mundy GD, Stanley S, Woods WE, Lehner A. Rees WA, Dirikolu L, Bass S, Karpiesiuk W, Carter WG, Boyles J, Tobin T:  Lidocaine in the horse:  Its pharmacological effects and their relationship to analytical findings.  J Vet Pharmacol Therap 21:462-476, 1998.

  278. Tobin T, Mundy GD, Stanley SD, Sams R, Jack RA:  The Commission Veterinarian Equine Medical Director:  A Short Course, Nov. 28- Dec. 1, 1995. In Preparation for Publ. 1997.

  279. Harkins JD, Carney JM, Meier M, Laek SC, Tobin T:  Effect of a-phenyl-tert-butylnitrone on endotoxin toxemia in horses.  Vet Human Toxicol 39 (5) October 1997:  pp 268-271. [KY Ag Exp Sta #95-14-077]

  280. Queiroz-Neto A, Zamur G, Goncalves SC, Carregaro AB Mataqueiro MI, Harkins JD,  Tobin T:  Characterization of the antinociceptive and sedative effect of amitraz in horses.  J Vet Pharmacol Therap, 21(5):400-405, 1997. [KY Ag Exp Sta #97-14-137].

  281. Tobin T, Mundy GD, Rees WA, Harkins JD, Woods WE, Lehner A, Karpiesiuk W, Dirikolu, Boyles J, Carter W:  Review of a consequence of highly sensitive drug testing:  The need for data on analytical-pharmacological relationships for therapeutic medication.  Proc 43rd Convent Am Assoc. Equine Pract, Phoenix, AZ, 1997, pp 215-219.

  282. Granstrom DE, McCrillis S, Wulff-Strobel C, Baker CB, Carter W, Harkins JD, Tobin T, Saville WJ:  Diclazuril and equine protozoal myeloencephalitis.  Proc 43rd Convent Am Assoc. Equine Pract, Phoenix, AZ, 1997, pp13-14.

  283. Tobin T, Dirikolu L, Harkins JD, Granstrom DE, Carter W, Lehner A, Rees WA:  Preliminary pharmacokinetics of diclazuril and toltrazuril in the horse.  Proc 43rd Convent Am Assoc. Equine Pract, Phoenix, AZ, 1997, pp15-16.

  284. Harkins JD, Tobin T, Queiroz-Neto A:  Development of an equine behavior chamber and effects of amitraz, detomidine and acepromazine on spontaneous locomotor activity. Proc 43rd Convent Am Assoc. Equine Pract, Phoenix, AZ, 1997, pp227-228.

  285. Queiroz-Neto A, Zamur G, Carregaro AB, Mataqueiro MI, Salvadori MC, Azevedo CP, Harkins JD, Tobin T:  Effects of caffeine on locomotor activity of horses: Determination of the no-effect threshold. J Applied Toxicol, 21:229-234, 2001.

  286. Rees WA, Holland RE, Dirikolu L, Tobin T, Chambers TM:  Therapeutic efficacy of rimantadine HCl in experimentally induced influenza: An illness in horses. Proc 43rd Convent Am Assoc. Equine Pract, Phoenix, AZ, 1997, pp390-391.

  287. Harkins, JD, Mundy GD, Karpiesiuk W, Woods WE, Dirikolu L, Carter WG, Boyles J, Tobin T:  Bupivacaine:  Pharmacological effects, analytical detection, and regulatory significance in performance horses.  In press, 1999.

  288. Woods WE, Lehner A, Karpiesiuk W, Harkins JD, Tobin T:  Detection and quantitation of 3-hydroxymepivacaine in horse urine.  Proc 12th Intl地 Conf Racing Analysts Vets, Vancouver, Canada, 1998, pp324-328. [KY Ag Exp Sta #98-14-35].

  289. Harkins JD, Mundy GD, Stanley SD, Woods WE, Sams RA, Richardson DR, Grambow SC, Tobin T: Absence of detectable pharmacological effects after oral administration of isoxsuprine. Equine Vet J 30(4):294-299, 1998. [KY Ag Exp Sta #96-14-142].

  290. Lehner A, Woods WE, Harkins JD, Karpiesiuk W, Boyles J, Carter WG, Dirikolu L, Tobin T:  Detection and quantitation of 3-hydroxybupivacaine in horse urine.  Proc 12th Intl地 Conf Racing Analysts Vets, Vancouver, Canada, 1998, pp287-291. [KY Ag Exp Sta #98-14-48]

  291. Harkins JD, Karpiesiuk W, Woods WE, Lehner A, Mundy GD, Rees WA, Dirikolu L, Bass S, Carter WG, Boyles J, Tobin T:  Mepivacaine:  Its pharmacological effects and their relationship to analytical finding in the horse.  J. Vet. Pharmacol. Therap, 22:107-121, 1999. [KY Ag Exp Sta #98-14-148].

  292. Tobin T:  Medication control from 1900 to the Present.  HBPA Medication Booklet, 1998, pp. 23-29. [KY Ag Exp Sta #97-14-138].

  293. Rees WA, Harkins JD, Lu M, Blouin RA, Holland RE, Lehner F, Chambers TM, Tobin T: Rimantadine and equine influenza: Pharmacology, pharmacokinetics, and therapeutic efficacy in the horse.  Equine Vet J, 29(2):104-110, 1996. [KY Ag Exp Sta #95-14-134].

  294. Harkins JD, Mundy GD, Stanley SD, Rees WA, Tobin T: An overview of the methylxanthines and their regulation in the horse.  Equine Practice, 20(1):10-16, 1998.  [KY Ag Exp Sta #96-14-084].

  295. Karpiesiuk W, Lehner A, Woods WE, Tobin T: Equine drug metabolites and standards.  Distributed, 1998.  Booklet published by Gluck Equine Research Center, Lexington, KY, 1998.

  296. Tobin T, Lehner A, Woods WE, Karpiesiuk W, Harkins JD: Detection and quantitation of 3-hydroxylidocaine in horse urine.  In press, Proc 12th Int値 Conf Racing Analysts Vets, Vancouver, Canada, 1998.

  297. Dirikolu L, Lehner A, Woods WE, Bentz B, Harkins JD, Carter W, Granstrom DE, Tobin T: Detection, quantification and preliminary pharmacokinetics of diclazuril in the horse.  Proc 12th Int値 Conf Racing Analysts Vets, Vancouver, Canada, 1998, pp240-244. [KY Ag Exp Sta #98-14-39].

  298. Tobin T, Saville W, Carter W, Cohen N, Divers T:  The interim report on workshop on equine protozoal myeloencephalitis:  Testing and treatment.  Manuscript distributed to workshop participants, 1998. [KY Ag Exp Sta #98-14-42].

  299. Dirikolu L, Lehner AF, Nattrass C, Bentz B, Woods WE, Carter W, Karpiesiuk W, Boyles J, Harkins JW, Granstrom DE, Tobin T: Diclazuril in the horse: Its identification, detection and preliminary pharmacokinetics. J Vet Pharm Therap, 22:374-379, 1999. [KY Ag Exp. Sta #98-14-70].

  300. Tobin T, Harkins JD, Sams RA: Testing for therapeutic medications: Analytical/pharmacological relationships and the need for 斗imitations on the sensitivity of testing for certain agents.  J Vet Pharm Therap, 22:220-233. 1999. [KY Ag Exp Sta #98-14-134].

  301. Harkins JD, Tobin T:  Lack of local efficacy of fentanyl in the abaxial sesamoid block model.   J Vet Pharm Therap, 22:52-55, 1999 [KY Ag Exp Sta #98-14-85].

  302. Heller TA, Tobin T, Karpiesiuk W, Tai H-H, Harkins JD, Magsig SE, Schroedter DE: ELISA assay for fluoxetine.  In press, Proc 12th Int値 Conf Racing Analysts Vets, Vancouver, Canada, 1998.

  303. Bentz BG, Dirikolu L, Carter WG, Saville W, Bernard WV, Wulff-Strobel C, McCrillis S, Reed S, Granstrom DE, Tobin T: Clinical report on diclazuril and equine protozoal myeloencephalitis (EPM). Equine Vet. Education, 2:258-263, 2000 [KY Ag Exp Sta #98-14-159].

  304. Bentz BG, Carter WG, Tobin T: Equine protozoal myeloencephaltis (EPM):  Review of a diagnostic approach.  Compendium on Continuing Education for Practicing Veterinarians, 21:975-981, 1999. [KY Ag Exp Sta #98-14-158].

  305. Harkins JD, Karpiesiuk W, Tobin T, Dirikolu L, Lehner AF:  Identification of hydroxyropivacaine glucuronide in equine urine by ESI+/MS/MS.  Can J Vet Res, 64(3):178-183. [KY Ag. Exp. Sta#98-14-151].

  306. Short CR, Sams RA, Soma LR, Tobin T:  The regulation of drugs and medicines in horse racing in the United States.  The Association of Racing Commissioners International Uniform Classification of Foreign Substances Guide.  J Vet Pharm Therap. 21, 144-153, 1998.

  307. Harkins JD, Karpiesiuk W, Woods WE, Lehner A, Dirikolu L, Carter W, Boyles J, Tobin T:  Ropivacaine in the horse:  Its pharmacological responses, urinary detection and mass spectral confirmation.  J Vet Pharm Therap, 24:89-98, 2001. [KY Ag. Exp. Sta #98-14-153].

  308. Tobin T:  Equine Drug Testing:  How it works, HBPA Medication Booklet, pp. 42-51, 1998 [KY Ag. Exp. Sta. #9814-26].

  309. Tobin T:  Dietary, environmental, and endogenous substances in horses. In Medication Reference Guide, National Horsemen痴 Benevolent & Protective Association, pp 52-58, 1998.

  310. Tobin T, Harkins JD, Carter W, Sams R Stanley S:  An interim report on the Testing Integrity Program seminar 擢urosemide in the Horse:  Its Actions, Effects and Regulatory Control.  The New Orleans Hilton, Riverside, CA, March, 1998.

  311. Bosken JM, Lehner AF, Hunsucker A, Harkins JD, Woods WE, Karpiesiuk W, Carter WG, Boyles J, Fisher M, Tobin T: Direct MS-MS identification of isoxsuprine-glucuronide in post-adminstration equine urine.  Can J Vet Res, 64:112-116, 2000. [KY Ag. Exp. Sta #99-14-3]

  312. Dirikolu L, Lehner AF, Karpiesiuk W, Harkins JD, Woods WE, Carter WG, Boyles J, Fisher M, Tobin T: Identification of lidocaine and its metabolites in post-administration equine urine by ELISA and MS-MS. J Vet Pharm Therap, 23:215-222, 2000. [KY Ag. Exp. Sta #00-14-91]

  313. Tobin T: Equine Forensic Science: An Overview of the Scientific Methods. Booklet Published by Gluck Equine Research Center, Lexington, KY, 1998. [KY Ag. Exp. Sta #98-14-192]

  314. Boyles J, Woods WE, Harkins JD, Fisher M, Uboh C, Tobin T: Procedures and quality assurance aspects of the Testing Integrity Program. Submitted to Proceedings of the 52nd Meeting of the Association of Official Racing Chemists, New Orleans, LA, 1999. [KY Ag. Exp. Sta #99-14-27]

  315. Harkins JD, et al: Clenbuterol in the horse: A Preliminary analytical report. Submitted to Proceedings of the 52nd Meeting of the Association of Official Racing Chemists, New Orleans, LA, 1999.

  316. Lehner AF, Hunsucker A, Bosken JM, Harkins JD, Woods WE, Karpiesiuk W, Almeida P, Dirikolu L, Carter WG, Boyles J, Holtz C, Fisher M, Tobin T: Further characterization of equine isoxsuprine metabolites by electrospray ionization tandem mass spectrometry.  Manuscript in preparation, 2003.

  317. Carregaro AB, Woods WE, Queiroz-Neto A, Tobin T: Comparison of the quantification of caffeine in human plasma by gas chromatography and ELISA.  Braz J Med Biol Res, 34:821-824, 2001. [KY Ag Exp Sta #01-14-116]

  318. Harkins JD, Robinson NE, Woods WE, Lehner AF, Smith MD, Gates RS, Fisher M, Tobin T: Intratracheal clenbuterol in the horse: Its pharmacological efficacy and analytical detection.  J Vet Pharmacol Therap, 23:251-260, 2000. [KY Ag. Exp. Sta #99-14-167]

  319. Lehner AF, Jacobs J, Almeida P, Harkins JD, Karpiesiuk W, Woods WE, Carter W, Boyles J, Dirikolu L, Bosken J, Holtz C, Tobin T: Qualitative identification of celecoxib in equine samples. Manuscript in preparation, 2003.

  320. Lehner AF, Almeida P, Jacobs J, Harkins JD, Karpiesiuk W, Woods WE, Dirikolu L, Bosken JM, Carter WG, Boyles J, Holtz C, Heller T, Nattrass C, Fisher M, Tobin T: Remifentanil in the horse: Identification and detection of its major urinary metabolite. J Analytical Toxicol, 24:309-315, 2000. [KY Ag. Exp. Sta #99-07-145]

  321. Ramsey EC, Carter W, Geiser D, Tobin T: Serum concentratins and effects of detomidine delivered orally to horses in three different mediums. Vet Anaesthesia and Analgesia, 29:219-222, 2002. [KY Ag Exp Sta #02-14-018]

  322. Harkins JD, Woods WE, Lehner AF, Karpiesiuk W, Hughes C, Gates RS, Fisher M, Tobin T: Pyrilamine in the horse: II. Detection and pharmacokinetics of pyrilamine and its major urinary metabolite. Manuscript in preparation, 2001.

  323. Xie H, Ott EA, Harkins JD, Tobin T, Colahan PT: Influence of electro-acupuncture on pain threshold in horses and its mode of action. Submitted to J Am Vet Med Assoc, 1999. [KY Ag. Exp. Sta # 99-14-170]

  324. Harkins JD, Woods WE, Lehner AF, Fisher M, Tobin T: Clenbuterol in the horse: Urinary concentrations determined by ELISA and GC/MS after clinical doses. J Vet Pharmacol Therap, 24:7-14, 2001. [KY Ag. Exp. Sta #00-14-49]

  325. Harkins, JD, Karpiesiuk W, Woods WE, Lehner A, Rees WA, Dirikolu L, Bass S, Carter WG, Boyles J, Tobin T: Ropivacaine in the horse: its pharmacological responses, urinary detection and mass spectral confirmation. J Vet Pharmacol Therap, 24:89-98, 2001.

  326. Lehner AF, Harkins JD, Karpiesiuk W, Woods WE, Robinson NE, Dirikolu L, Fisher M, Tobin T: Clenbuterol in the horse: Confirmation and quantitation of serum clenbuterol by LC-MS-MS after oral and intratracheal administration. J Analyt Toxicol, 25:280-287, 2001. [KY Ag. Exp. Sta #00-14-122]

  327. Woods WE, Harkins JD, Lehner AF, Dirikolu L, Karpiesiuk W, Boyles J, Carter WG, Fisher M, Heller T, Tobin T: Detection and disposition of pyrilamine and its metabolite O-desmethylpyrilamine in equine blood and urine: A preliminary report. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, pp472-477. [KY Ag. Exp. Sta # 00-14-85]

  328. Dirikolu L, Lehner AF, Jacobs J, Woods WE, Karpiesiuk W, Harkins JD, Carter WG, Boyles J, Hughes C, Bosken JM, Holtz C, Nattrass C, Fisher M, Tobin T: Celecoxib in the horse: Its recovery, mass spectrometric identification, disposition and major urinary metabolites. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, pp162-170. [KY Ag. Exp. Sta #00-14-101]

  329. Carter WG, Walters K, Chamblin T, Tobin T: A review of Association of Racing Commissioners International class 1, 2 and 3 medication violations and penalties for 1995-1999 in North America. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, pp303-309.

  330. Holtz C, Drinnon R, Gates R, Hughes CG, Woods WE, Sweet A, Dirikolu L, Bosken JM,  Harkins JD, Lehner AF, Carter WG, Karpiesiuk W, Boyles J, Fisher MG, Tobin T: The postural signature device: A non-invasive tool for identifying medication thresholds. A preliminary report. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, pp46-52. [KY Ag. Exp. Sta #00-14-110]

  331. Lehner AF, Almeida P, Harkins JD, Karpiesiuk W, Woods WE, Dirikolu L, Bosken JM, Carter WG, Boyles J, Holtz C, Heller T, Nattrass C, Fisher M, Tobin T: Identification and detection of the major equine urinary metabolite of remifentanil. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, pp465-471. [KY Ag. Exp. Sta #00-14-104]

  332. Lehner AF, Woods WE, Karpiesiuk W, Harkins JD, Fisher M, Tobin T: A highly sensitive detection method for clenbuterol in equine serum. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, pp420-426. [KY Ag. Exp. Sta #00-14-103]

  333. Lehner AF, Hughes C, Woods WE, Karpiesiuk W, Harkins JD, Dirikolu L, Holtz C, Bosken JM, Carter WG, Boyles J, Booze R, Mactutus C, Fisher M, Tobin T: A liquid chromatographic-electrospray tandem MS/MS method for quantitation of equine cocaine metabolites. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, pp413-419. [KY Ag. Exp. Sta #00-14-105]

  334. Patrick S, Heller T, Tobin T, Bratton C, Bass S: Fentanyl group ELISA for the detection of remifentanil and other narcotic analgesics. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, pp337-340.

  335. Karpiesiuk W, Lehner AF, Tobin T: Synthesis and characterization of deuterated clenbuterol and two equine metabolites. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, 427-429. [KY Ag. Exp. Sta #01-14-8]

  336. Bosken JM, Tobin T, Mundy GD, Fisher M, Banks RO: Comparison of specific gravity and osmolality in post-race urine of furosemide-treated and control Thoroughbred horses. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, pp345-349.

  337. Dirikolu L, Bentz BG, Lehner AF, Woods WE, Harkins JD, Karpiesiuk W, Carter WG, Boyles J, Granstrom D, Tobin T: New therapeutic approaches to equine protozoal myeloencephalitis: Clinical pharmacology and apparent efficacy of diclazuril, toltrazuril and sulfonotoltrazuril. Submitted to J Vet Pharmacol Therap, 2001. [KY Ag. Exp. Sta #00-14-102]

  338. Tobin T, Harkins JD, Fisher M: 鮮o-effect limits: An overview and a pharmacological approach. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, pp36-42. [KY Ag. Exp. Sta #00-14-198]

  339. Hale ND, Tobin T, Tai H-H, Harkins JD, Heller T, Schroedter DE, Bratton C, Mayer B: ELISA assay for stanozolol. Proc 13th Int値 Conf Racing Analysts Vets, Cambridge, UK, 2000, pp341-344.

  340. Harkins JD, Dirikolu L, Lehner AF, Hughes C, Schroedter D, Mayer B, Bratton C, Fisher M, Tobin T: The detection and biotransformation of guanabenz in horses: A preliminary report. Vet Ther, 4(2): 197-209, 2003. [KY Ag. Exp. Sta. #01-14-113]

  341. Harkins JD, Lehner AF, Woods WE, Tobin T: Guanabenz in the horse: Clinical effects and its comparison with other a2 agonists. Manuscript in preparation, 2003.

  342. Dirikolu L, Lehner AF, Hughes C, Woods WE, Karpiesiuk W, Harkins JD, Boyles J, Granstrom DE, Tobin T: Toltrazuril sulfone in the horse: Its identification, detection and pharmacokinetics. Manuscript in preparation, 2001.

  343. Dirikolu L, Lehner AF, Karpiesiuk W, Hughes C, Woods WE, Carter WG, Boyles J, Harkins JD, Tobin T: Detection, quantification, metabolism and behavioral effects of selegiline in the horse. Veterinary Therapeutics, 4(3):257-268, 2003. [KY Ag. Exp. Sta. #01-14-186]

  344. Bosken J, Lehner AF, Woods WE, Hughes CG, Harkins JD, Boyles J, Tobin T: A GC/MS method for the determination of isoxsupriュne in biological fluids of the horse utilizing electron impact ionization. Manuscript submitted to J Anal Tox, 2003.

  345. Dirikolu L, Lehner AF, Hughes C, Woods WE, Karpiesiuk W, Harkins JD, Boyles J, Granstrom DE, Tobin T: Sodium salt formulations of diclazuril and toltrazuril sulfone in the horse: Identification, synthesis, detection and pharmacokineticュs. Manuscript in preparation, 2001.

  346. Dirikolu L, Mollett BA, Woods WE, Lehner AF, Karpiesiuk W, Boyles J, Harkins JD, Bratton C, Tobin T: Apparent ELISA detection times for albuterol after administration with the torpex equine inhaler device. Vet Ther 3(3):297-307, 2002. [KY Ag Exp Sta #02-14-30]

  347. Lehner AF, Craig AM, Fannin N, Bush L, Tobin T: Fragmentation patterns of selected ergot alkaloids by electrospray ionization tandem quadrupole mass spectrometry. J Mass Spec, 39(11):1275-862003. [KY Ag Exp Sta #02-14-60]

  348. Dirikolu L, Mollett BA, Woods WE, Bratton C, Lehner AF, Karpiesiuk W, Hughes C, Boyles J, Harkins JD, Troppmann A, Tobin T: ELISA 電etection times of albuterol after Torpex administration: a preliminary report. In press, Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002.

  349. Hughes C, Lehner AF, Crutchfield J, Woods WE, Harkins JD, Karpiesiuk W, Dirikolu L, Sebastian M, Troppmann A, Boyles J, Bosken J, Harrison L, Tobin T: Analytical detection and 渡ormal population data of cyanide and thiocyanate in equine blood and serum. In press, Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002. [KY Ag Exp Sta #02-14-168]

  350. Harkins JD, Tobin T: Pharmacodynamics of guanabenz and related α2 agonists. In press, Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002. [Abstract only]

  351. Lehner AF, Hughes C, Woods WE, Harkins JD, Karpiesiuk W, Dirikolu L, Bosken J, Boyles J, Troppmann A, Fisher M, Tobin T: Proposed methodology for the detection of Oxyglobinョ in equine plasma. In press, Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002. [KY Ag Exp Sta #02-14-169]

  352. Karpiesiuk W, Lehner AF, Dirikolu L, Fisher M, Tobin T: Synthesis and characterization of deuterated standard of furosemide (Salixョ). In press, Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002. [KY Ag Exp Sta #02-14-181]

  353. Dirikolu L, Lehner AF, Hughes C, Karpiesiuk W, Camargo FC, Harkins JD, Woods WE, Bosken J, Boyles J, Troppmann A, Fisher M, Tobin T: Detection, quantification and pharmacokinetics of furosemide in horses: a preliminary report. In press, Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002. [Ky Ag Exp Sta #03-14-070]

  354. Casey PJ, Champion ZJ, Mansell KB, Tobin T: Stallion influence on reproductive loss during Mare Reproductive Loss Syndrome (MRLS) in Lexington, Kentucky 2001. Abstract submitted to Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002.

  355. Casey PJ, Korolev AB, Baker IDC, Champion ZJ, Tobin T: The effect of intermittent hypoxic training (IHT) on haematological values, aerobic capacity and performance in racing thoroughbreds. Abstract submitted to Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002.

  356. Lehner AF, Meek J, True J, Harkins JD, Karpiesiuk W, Hughes CG, Dirikolu L, Woods WE, Bosken J, Boyles J, Troppmann A, Fannin N, Bush L, Craig AM, Tobin T: Ergot alkaloids screened by HPLC-electrospray[+] tandem quadrupole mass spectrometry.  Manuscript accepted by J Anal Tox, 2002. [KY Ag Exp Sta# 02-14-61]       

  357. Hughes CG, Sebastian M, Crutchfield J, Dirikolu L, Harkins JD, Boyles J, Troppmann A, McDowell K, Harrison L, Tobin T: A simple, rapid and highly sensitive spectrophotometric method for determination of cyanide in equine biological samples. Toxicology Mechanisms and Methods 13:129-138, 2003. [KY Ag Exp Sta# 02-14-85]

  358. Dirikolu L, Sebastian M, Hughes CG, Crutchfield J, Harkins JD, Boyles J, Troppmann A, McDowell K, Harrison L, Tobin T: The toxicokinetics of cyanide and mandelonitrile in the horse and their relevance to the Mare Reproductive Loss Syndrome. Toxicology Mechanisms and Methods, 13:199-211, 2003. [KY Ag Exp Sta# 02-14-86]

  359. Tobin T, McDowell K, Hughes CG, Lehner AF, Crutchfield J, Harkins JD, Dirikolu L, Sebastian M, Harrison L, Williams N, Smith R, Webb B, Newman K, Allman R, Dwyer R, Powell D: The Kentucky 2001 Mare Reproductive Loss Syndrome: overview and preliminary toxicological approaches. Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002. p. 261.

  360. Camargo F, Dirikolu L, Sebastian M, Hughes C, Crutchfield J, Harkins JD, Boyles J, Troppmann A, McDowell K, Harrison L, Tobin T: The pharmacokinetics of cyanide and mandelonitrile in the horse and their relevance to the Mare Reproductive Loss Syndrome. In press, Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002. [KY Ag Exp Sta #03-14-071]

  361. Queiroz-Neto A, Zamur G, Lacerda-Neto C, Tobin T: Determination of the Highest No-effect Dose (HNED) and of the elimination pattern for cocaine in horses. J Appl Toxicol 22:117-121, 2002. [KY Ag Exp Sta #02-14-156]

  362. Powell DG, Troppmann A, and Tobin T (eds): Proceedings of the First Workshop on Mare Reproductive Loss Syndrome. Lexington, KY, 2002. Published 2003.

  363. Mayer BA, Tobin T, Tai HH, Harkins JD, Carbajal J, Scherer C, Hawkins T, Bratton C, Schroedter DE: Detection of selegiline and selegiline metabolites in an ELISA assay for amphetamine. Manuscript submitted to Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002.

  364. Mayer BA, Tobin T, Tai HH, Harkins JD, Hawkins T, Bratton C, Schroedter DE: ELISA assay for ketamine. Manuscript submitted to Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002.

  365. Mayer BA, Tobin T, Tai HH, Harkins JD, Hale ND, Bratton C, Schroedter DE: ELISA assay for guanabenz. Manuscript submitted to Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002.

  366. Mayer BA, Tobin T, Tai HH, Harkins JD, Hale ND, Bratton C, Scherer C, Schroedter DE: ELISA assay for apomorphine. Manuscript submitted to Proc 14th Int値 Conf Racing Anaュlysts Vets, Orlando, FL, 2002.

  367. Harkins JD, Dirikolu L, Sebastian M, Hughes C, Crutchfield J, Troppmann A, Boyles J, Webb B, McDowell K, Long W, Henning J, Harrison L, Fitzgerald T, Tobin T: Cherry trees, plant cyanogens, caterpillars and Mare Reproductive Loss Syndrome: Toxicological evaluation of a working hypothesis. In Powell DG, Troppman A, Tobin T (eds), Proc First Workshop on Mare Reproductive Loss Syndrome, Lexington, KY, 2002, pp68-74. [KY Ag Exp Sta # 02-14-167]

  368. Dirikolu L, Lehner AF, Hughes CG, Karpiesiuk W, Camargo F, Harkins JD, Woods WE, Bosken JM, Boyles J, Troppmann A, Fisher M, Tobin T: The detection, quantification and pharmacokinetics of furosemide and its effects on urinary specific gravity following intravenous administration to horses. Manuscript in press, Veterinary Therapeutics, 2003. [KY Ag. Exp. Sta. #03-14-104]

  369. Champion ZJ, Breier BH, Ewen WE, Tobin T, Casey PJ: Blood plasma concentrations of insulin-like growth factor-1 (IGF-1) in resting standardbred horses. The Vet J 163:45-50, 2002.

  370. Sebastian M, Williams D, Harrison L, Donahue J, Seahorn T, Slovis N, Richter D, Fuller T, Trail C, Douglas R, Tobin T: Experimentally Induced Mare Reproductive Loss Syndrome Late Fetal Losses with Eastern Tent Caterpillars. In Powell DG, Troppman A, Tobin T (eds), Proc First Workshop on Mare Reproductive Loss Syndrome, Lexington, KY, 2002, pp80-81.

  371. Sebastian M, Harkins JD, Jackson C, Fuller T, Trail C, Richter D, Harrison L, and Tobin T: A laboratory animal model of Mare Reproductive Loss Syndrome: preliminary evaluation of a mouse model. In Powell DG, Troppman A, Tobin T (eds), Proc First Workshop on Mare Reproductive Loss Syndrome, Lexington, KY, 2002, pp51-53.

  372. Bosken JM, Tobin T, Mundy G, Fisher M, Gantz MG, Banks RO: Effect of furosemide on urine specific gravity and osmolality in Thoroughbred racehorses. Veterinary Therapeutics, 4(3):292-298, 2003. [Ky Ag Exp Sta # 02-14-180]

  373. Lehner AF, Hughes CG, Karpiesiuk W, Harkins JD, Dirikolu L, Bosken J, Camargo F, Boyles J, Troppmann A, Woods WE, Tobin T: Development of a method for the detection and confirmation of the α2-agonist amitraz and its metabolites in horse urine. Manuscript accepted by J Anal Tox, 2003.

  374. Tobin T: Septic Penetrating Setae/Septic Emboli/Septic Penetrating Setal Emboli (SPS/SE/SPSE): A hypothesis to explain the pathogenesis of the Mare Reproductive Loss Syndrome. Copyright registered at Library of Congress, June 17, 2003, #TXU1111484.

  375. Lehner AF, Hughes CG, Harkins JD, Nickerson C, Mollett B, Dirikolu L, Bosken JM, Camargo F, Boyles J, Troppmann A, Karpiesiuk W, Woods WE, Tobin T: Detection and confirmation of ractopamine and its metabolites in horse urine after Paylean(R) administration. Manuscript accepted by J Anal Tox, 2003. [KY Ag Exp Sta # 03-14-041]

  376. Tobin T: The past and future of equine drug testing and medication regulation. Proc 24th Bain-Fallon Memorial Lectures, Gold Coast, Australia, 2002, pp.8-12.

  377. Tobin T: Factors affecting 電etection times and 努ithdrawal times for NSAIDs. Proc 24th Bain-Fallon Memorial Lectures, Gold Coast, Australia, 2002, pp.13-17.

  378. Tobin T: Pre-purchase and drug testing of horses: a review. Proc 24th Bain-Fallon Memorial Lectures, Gold Coast, Australia, 2002, pp. 18-22.

  379. Tobin T: The Mare Reproductive Loss Syndrome: an ongoing toxicological/other investigation. Submitted to Proc 24th Bain-Fallon Memorial Lectures, Gold Coast, Australia, 2002.

  380. Stirling K, Bellocq R, and Tobin T: National Horsemen痴 Benevolent and Protective Association, Inc. Proposed National Policy on Drug Testing and Therapeutic Medication. J Eq Vet Sci 23(1): 4-5, 18-40, 2003. [Ky Ag Exp Sta# 03-14-072]

  381. Sebastian MM, Gantz M, Tobin T, Harkins JD, Bosken JM, Hughes CG, Harrison LR, Bernard WV, Richter D and Fitzgerald TD: Eastern tent caterpillars and the Mare Reproductive Loss Syndrome: Clinical, epidemiological and mechanistic implications of a toxicokinetic/statistical analysis. Manuscript submitted to Veterinary Therapeutics, 2003.

  382. Tobin T: Summary, Session 5: MRLS and Associated Syndromes: Toxicological Hypotheses. In Powell DG, Troppman A, Tobin T (eds), Proc First Workshop on Mare Reproductive Loss Syndrome, Lexington, KY, 2002, p75.

  383. Harkins JD, Dirikolu L, Lehner AF, Hughes CG, Woods WE, Schroedter D, Mayer B, Bratton C, Fisher MV, Tobin T: Short Communication: A rapid and sensitive Enzyme Linked ImmunoSorbent Assay (ELISA) test for guanabenz in the horse. Manuscript in preparation, 2003.

  384. Tobin T: Test of time. The Blood Horse, November 17, 1990, pp. 6188-6190.

  385. Carter WG, Troppmann A, Tobin T, Franklin B: An overview of the effective world rules on therapeutic medications. Booklet published by Gluck Equine Research Center.

  386. Mundy GD, Stanley SD, Tobin T: Analysis of prohibited substances in Kentucky with emphasis on strategies for practitioュners to avoid problems. Proc 41st Convent Am Assoc Equine Pract, Lexington, KY, 1995, pp160-162.

  387. Tobin T, Harkins JD, Woods WE, Queiroz-Neto A, Stanley SD, Mundy GD: Overュview of diュetary, enviュronュmenュtal, and endogeュnous subュstancュes of regulatoュry concern in racing horses. Proc 41st Convent Am Assoc Equine Pract, Lexington, KY, 1995, pp156-159.

  388. Tobin T: Trace Level Benzoylecgonine Identifications in Post-Race Urines: Probable Sources and the Regulatory Significance of Such Identifications, HBPA Booklet pubュlished by Gluck Equine Reュsearch Center, Lexington, KY, 2000.  Also: Appendix II: Currently in place 斗imits or 田utoffs or thresholds for cocaine/benzoylecgonine.

  389. Rees WA, Harkins JD, Lu M, Holland RE, Lehner A, Tobin T, Chambers TM: Pharmacokinetics and therapeutic efficacy of rimantadine in horses experimentally infected with influenza virus A2. Am J Vet Res, 60:888-894, 1999. [KY Ag Exp Sta #96-14-131].

  390. Harkins JD, Queiroz-Neto A, Mundy GD, West D, Tobin T: Development and characterization of an equine behavior chamber and the effects of amitraz and detomidine on spontaneous locomotor activity. J Vet Pharmacol Therap, 20:396-401, 1997.

  391. Harkins JD, Lehner A, Karpiesiuk W, Woods WE, Dirikolu L, Boyles J, Carter WG, Tobin T: Bupivacaine in the horse: Relationship of local anaesthetic responses and urinary concentrations of 3-hydroxybupivacaine. J Vet Pharmacol Therap, 22:181-195, 1999. [KY Ag Exp Sta #98-14-166]

  392. Dirikolu L, Lehner AF, Karpiesiuk W, Hughes C, Woods WE, Bosken J, Carter WG, Boyles J, Harkins JD, Tobin T: Detection of selegiline and its major urinary metabolite, N-desmethylselegilinュe, in equine urine: A preliminary report. Submitted to Proceedings of the 54th Meeting of the Association of Official Racing Chemists, Lexington, KY, 2001.[KY Ag Exp Sta #01-14-186]

  393. Tobin T, Harkins JD, Lehner AF, Woods WE, Karpiesiuk W, Dirikolu L, Carter W, Boyles J, Sams RA: An overview of analytiュcal/pharmacological relationships and the need for limitaュtions on the sensitivity of testing for certain agents. Proc 12th Int値 Conf Racing Anaュlysts Vets, Vancouver, Canada, 1998, pp210-216. [KY Ag Exp Sta #98-14-50]

  394. Lehner AF, Hughes CG, Karpiesiuk W, Harkins JD, Bosken JM, Camargo F, Boyles J, Troppmann A, Woods WE and Tobin T: (2004) Metabolism of the α2-agonist amitraz in horses and confirmation of its administration, Proc 15th Intl Conf Racing Analysts Vets, pp. 155-160 [KY Ag Exp Sta #04-14-010].

  395. Lehner AF, Hughes CG, Harkins JD, Bosken JM, Camargo F, Boyles J, Troppmann A, Karpiesiuk W, Woods WE and Tobin T(2004) Metabolism of the beta-adrenergic agonist ractopamine in horses and confirmation of its administration with GC/MS. 15th Intl Conf Racing Analysts Vets, pp.93-98 [KY Ag Exp Sta #04-14-008]

  396. Hughes CG, Lehner AF, Harkins JD and Tobin T: Preliminary report on the confirmation and quantitative determination of salmeterol in equine urine. Proc 15th Intl Conf Racing Analysts Vets, 2004. p. 406-411[KY Ag Exp Sta #04-14-009]

  397. Gantz MG, Harkins JD, Sebastian M, Bosken J, Hughes CG, Harrison L, Bernard WV, Richter D, Fitzgerald TD and Tobin T: A toxicokinetic/Accelerated Failure Time Analysis of the Mare Reproductive Loss Syndrome (MRLS). Proc 15th Intl Conf Racing Analysts Vets, 2004. p212-217 [KY Ag Exp Sta #04-14-020]

  398. Tobin T: Septic Penetrating Setae/Bacteria/Bacterial Emboli/Septic Penetrating Setal Emboli (SPS/B/BE/SPSE): A hypothesis to explain the pathogenesis of Mare Reproductive Loss Syndrome. 15th Intl Conf Racing Analysts Vets, p. 418-422 , 2004.

  399. Karpiesiuk W, Lehner AF and Tobin T: Synthesis and certification of salmeterol and salmeterol-d12 standards. Proc 15th Intl Conf Racing Analysts Vets, 2004. p405

  400. Tobin T, Harkins JD, VanMeter PW, Fuller TA: The Mare Reproductive Loss Syndrome II: Clinical evaluation of the syndrome and a proposed mechanism: septic penetrating setae. Int J Applied Res in Vet Med, 2004.

  401. Lehner AF, Hughes CG, Harkins JD, Karpiesiuk W, Camargo F, Boyles J, Woods WE and Tobin T: Detection and identification of dizocilpine and its major urinary metabolites in the horse: a preliminary report. Chromatographia 59:S95-S103, 2004. [KY Ag Exp Sta #04-14-003]

  402. Lehner AF, Hughes CG, Karpiesiuk W, Camargo FC, Harkins JD, Woods WE, Bosken J, Boyles J, Troppmann A and Tobin T: Determination of salmeterol in equine urine and serum. Chromatographia 59:S79-S84, 2004. [KY Ag Exp Sta# 04-14-011]

  403. Hall NC, Yang J-M, Stanley SD, Mundy GD, Kryscio R, Tai HH, Rees WA Blake JW, Woods WE and Tobin T: Number of negative tests required to exclude specified levels of agent abuse in equine forensic chemistry. Manuscript in progress, 2004.

  404. Karpiesiuk W, Lehner AF, Hughes CG, and Tobin T (2004): Preparation and Chromatographic Characterization of tetrahydrogestrinone (THG), a New 電esigner Anabolic Steroid. Chromatographia, 60, 359-363. [KY Ag Exp Sta #04-14-052

  405. Dirikolu L, Karpiesiuk W, Lehner AF, Hughes, C., Woods WE, Harkins JD, Boyles J, Atkinson A, Granstrom D, and Tobin T. (2004) New Therapeutic Approaches for Equine Protozoal Myelitis: Synthesis and Pharmacokinetics of Diclazuril Sodium Salt in the Horse: Proceedings of the 15th International Conference of Racing Analysts and Veterinarians, Dubai, pp 135-140

  406. Karpiesiuk W, Lehner AF, Hughes CG, Guan F, Uboh C, Soma L, Bratton C, Kellerman L and Tobin T: (2004) Preparation and analysis of tetrahydrogestrinone (THG), a recently reported 電esigner anabolic steroid. Proc 15th Intl Conf Racing Analysts Vets,.p518-522

  407. Camargo FC, Lehner AF, Karpiesiuk W, Stirling K., Kavanagh PV, Brennan N, Dowling M., and Tobin T. (2005) Review of Environmental Morphine Identifications: World wide occurrences and Responses of Authorities.  AAEP Proc. vol. 61 p58-64

  408. Guan F, Uboh CE, Soma LR, Luo Y, Rudy J, and Tobin T., (2005) Detection, quantification and confirmation of anabolic steroids in equine plasma by liquid chromatography and tandem mass spectrometry. Journal of Chromatography B 829 5668.

  409. Tobin T., Camargo FC, Lehner AF, and Karpiesiuk W. (2005)  Drugs Medications and Performance Altering Substances: Their Performance Effects, Detection and Regulation: From 1800 to Keenland Oct 12th 2005

  410. Camargo FC, Robinson NE, Berney C, Eberhart S, Baker S, DeTolve P, Derksen FJ, Harkins JD, Lehner AF, and Tobin T. 2006. Intravenous and intratracheal administration of trimetoquinol, a fast-acting short-lived bronchodilator in horses with 'heaves'. Equine Vet J. 38(6):563-9

  411. Tobin T, Hughes C, Lehner AF, Camargo FC: (2006) Synthesis of deuterated analytical standards:  Ketoprofen-d3 and Flunixin-d3. Proceedings of the 16th International Conference of Racing Analysts and Veterinarians, Tokyo, Japan, pp214-217

  412. Camargo FC, Hughes C, Lehner AF and Tobin T. (2006) Trace Level Benzoylecgonine Identifications in Post-Race Urines: Probable Sources and the Regulatory Significance of Such Identifications. AAEP Proc. Vol. 52 p331-336

  413. Camargo FC, Robinson NE, Berney C, Eberhart S, Baker S, Detolve P, Derksen FJ, Lehner AF, Hughes C, Tobin T. (2007) Trimetoquinol: bronchodilator effects in horses with heaves following aerosolised and oral administration. Equine Vet J. 39(3):215-20

  414. Budharaja A., Camargo FC,  Hughes C, Lehner AF,  Stirling K., Brennan N, Dowling M., and Tobin T (2007) Caffeine and Theobromine Identifications in Post race Urines: Threshold Levels and Regulatory Significance of Such Identifications. AAEP Proc. Vol. 53 p87-92.

  415. Lehner AF, Stewart J, Dafalla A, Ely KJ, Connerly AL, Jones CN, ElkHoly H, Thompson K, Tobin T, Dirikolu L. (2007) Gabapentin in horses: validation of an analytical method for gabapentin quantitation. J Anal Toxicol. 31(9):555-65

  416. Camargo FC, Robinson NE, Dirikolu L, Berney C, Eberhart S, Derksen FJ, Lehner AF, May J, Hughes C,Tobin T., (2008) Plasma and urinary concentrations of trimetoquinol by LC-MS-MS following intravenous and intra-tracheal administration to horses with heaves. J Vet Pharmacol Ther 31(6):501-10

  417. Dirikolu L, Dafalla A, Ely KJ, Connerly AL, Jones CN, ElkHoly H, Lehner AF, Thompson K, and Tobin T.(2008) Pharmacokinetics of gabapentin in horses. J Vet Pharmacol Ther. 31(2):175-7.

  418. Spencer WA, Camargo FC, Karpiesiuk  W., Stirling K., Casey PJ, and Tobin T. (2008). Review of the Current Status of Thresholds/Withdrawal Time Guidelines for Therapeutic Medications in Performance Horses. AAEP proc. Vol.54 p29-37

  419. Dirikolu L., Woods WE, Boyles J.,  Lehner A F,  Harkins JD,  Fisher M, Schaeffer DJ and  Tobin T (2008)  Nonsteroidal anti-inflammatory agents and musculoskeletal injuries inThoroughbred racehorses in Kentucky J. vet. Pharmacol. Therap. doi: 10.1111/j.1365-2885.2008.01038.x

  420. Dirikolu L, Lehner AF, Hughes C, Karpiesiuk, W  and Tobin T: (2008) New Therapeutic Approaches to Equine Protozoal Myelitis: Pharmacokinetics of Toltrazuril Sulfone Sodium Salts in the Horse AAEP Proc. Vol.54 p191

  421. Lehner AF, Fitzgerald BP, Hughes CG, Tobin T, Camargo FC., May J, Dirikolu L, Christiansen DL, and Ryan PL. (2008) Serum concentrations of ergovaline/ergot alkaloids in late-term pregnant mares grazing entophyte infected tall fescue pastures: A preliminary  report.  Theriogenology 70 (2008) p583

  422. Dirikolu L, Lehner AF, Harkins JD, Woods WE, Karpiesiuk W, Gates RS, Fisher M, Tobin T: (2009) Pyrilamine in the horse: Detection and pharmacokinetics of pyrilamine and its major urinary metabolite 徹-desmethylpyrilamine. J Vet Pharmacol Ther. 2009 Feb;32(1):66-78

  423. Lehner AF, Petzinger E, Stewart J, Lang DG, Johnson MB, Harrison L, Seanor JW, Tobin T. (2009) ESI+MS/MS confirmation of canine ivermectin toxicity J Mass Spectrom.44(1):1119.

  424. Dirikolu L, Karpiesiuk W, Lehner AF, Hughes, C, Granstrom D and  Tobin, T (2009) Effect of Dimethylsulphoxide On Oral bioavailability Of a Triazine Based Antiprotozoalagent Toltrazuril Sulfone In The Horse. Proceedings of the 17th International Conference of Racing Analysts and Veterinarians, Antalya, Turkey. pp.315-320

  425. Dirikolu L, Woods WE, Boyles J, Lehner AF, Harkins JD, Fisher M, Schaeffer DJ and Tobin T.(2008) Nonsteroidal Anti-Inflammatory Agents And Musculoskeletal Injuries In Thoroughbred Racehorses In Kentucky. Proceedings of the 17th International Conference of Racing Analysts and Veterinarians, Antalya, Turkey. pp 329-333

  426. Dirikolu L, Karpiesiuk W, Lehner AF, Hughes, C, Granstrom D and  Tobin, T (2009) Synthesis and Detection Of Toltrazuril Sulfone and Its Pharmacokinetics In Horses Following Administration In Dimethylsulfoxide. J Vet Pharmacol Ther. 2009 Aug; 32(4):368-78

  427. Dhanjal JK, Wilson DV, Robinson NE and Tobin T (2009) Intravenous Tramadol: Effects, Nociceptive Properties, and Pharmacokinetics in Horses. Veterinary Anaesthesia and Analgesia 36, 581-590.

  428. Dhanjal JK, Wilson DV, Hughes CG, Karpiesiuk W, Spencer W, Tharappel J, Dirikolu L, Lehner A and Robinson NE (2008) Tramadol in the Horse: A Preliminary Report on its Detection, Pharmacokinetics and Pharmacodynamics Responses. Proceedings of the 17th International Conference of Racing Analysts and Veterinarians, Antalya, Turkey, pp 106-115.

  429. Dirikolu L, Karpiesiuk, W, Lehner F and Tobin T., Toltrazuril Sulfone Sodium Salt: Synthesis, Analytical Detection, and Pharmacokinetics in the Horse J Vet Pharmacol Ther 2011 Kentucky Ag Expt Station Number 11-14-046

  430. Thomas Tobin and Kent H. Stirling (2009) Equine Drug Testing & Therapeutic Medication Regulation; 2009 Policy of the National Horsemen's Benevolent and Protective Association, Inc. Wind Publications, 600 Overbrook Dr, Nicholasville, KY 40356, USA pp 170

  431. Tobin T, Eisenberg, R., Gutierrez, J., Long, S., Li, T., Tharappel, J., Hughes, C., Armstrong, E., Mayer, B., Stanley, E., Lyons, M and Karpiesiuk, W. (2010) Certified Reference Standards and Stable Isotope Internal Standards for Equine Therapeutic Medication Regulation. In press, Proceedings of the 18th International Conference of Racing Analysts and Veterinarians,Queens Town, New Zealand

  432. Tobin, T., Gutierrez, J., and Eisenberg, R., (2010) Experiences as an Expert: Educating People While Under Oath, 25 Years since Hong Kong.  In press, Proceedings of the 18th International Conference of Racing Analysts and Veterinarians,QueensTown, New Zealand

  433. Rich Harden and Thomas Tobin (2010) 鉄hipping In A Risk Factor Associated with Fatal Musculoskeletal Racing Injuries. Submitted for publication, J Eq Vet Sci

  434. Tobin, T.,Koval, N. and Harden, R.,(2010)  Fatal Musculoskeletal Injury Rates and Regulatory Thresholds for Phenylbutazone, in final draft

  435. Gutierrez J, Eisenberg RL, Koval NJ, Armstrong ER., Tharappel J, Hughes CG, Tobin, T (2010) Pemoline and Tetramisole 撤ositives In English Racehorses Following Levamisole Administration.  Irish Vet J 63 (8) 498-500

  436. Race for the Prize (2010) Robert Hogan Interviews Thomas Tobin in Irish Veterinary Journal. Irish Vet J 63 (8) 482-484.

  437. Julio Gutierrez, Rodney Eisenberg, Gabrielle Herrensmith, Thomas Tobin, Tonglei Li* and  Sihui Long * Conformational Polymorphism in 2-((4-hydroxy-2,6-dimethylphenyl) amino)-5,6-dihydro-4H-1,3-thiazin-3-ium Chloride,  2010, C66, p 593-595, Acta Crystallographica Section C: Crystal Structure Communications. Ky Ag Expt Station Numberr 10-14-123 UK #392. PMID: 21123891 [PubMed]

  438. Helieh S. Oz1,2, DVM, MS, PhD, AGAF ; Thomas Tobin3, MVB, MSc, PhD, MRCVS, DABT Efficacy of Diclazuril Protection in a Mouse Model of Fetal Toxoplasmosis, in final draft 2011 UK #395.

  439. Gutierrez Julio a, Rodney Eisenbergb, Gabrielle Herrensmitha, Thomas Tobina, Tonglei Lic, Sihui Longc* Solvatomorphism in E)-2-(2,6-dichloro-4-hydroxybenzylidene)hydrazinecarboximidamide, Submitted for publication February 2011, Acta Crystallographica Reference: sq3285  UK# 394, PMID: 21817799  [PubMed]

  440.   Lehner Andreas F., Jennifer M. Duringerb, Charles T. Estillc, Thomas Tobind, A. Morrie Craige  ESI-Mass spectrometric and HPLC elucidation of a new ergot alkaloid from perennial ryegrass hay silage associated with bovine reproductive problems, In press, Toxicology Mechanisms and Methods, 2011 KAES Article # 11-14-031 UK # 396.

  441. Thomas Tobin Kimberly Brewer, and Kent H. Stirling (2012) World Rules for Equine Drug Testing and Therapeutic Medication Regulation; 2012 Policy of the National Horsemen's Benevolent and Protective Association, Inc. Wind Publications, 600 Overbrook Dr, Nicholasville, KY 40356, USA pp 370  KAES Article # 11-014-096 UK # 397 .

  442. Julio Gutierrez, Rod Eisenberg, Elizabeth Marie Ferguson, Charlie Hughes and Thomas Tobin  鉄ynthesis of myo-inositol trispyrophosphate (ITPP)  for use as an analytical standard Submitted for publication, 18th international conference of racing analysts and veterinarians, Philadelphia Pennsylvania, September 15-22, 2012

  443. Thomas Tobin, Richard H Galley, Kimberly Brewer, Abelardo Morales Briceno and Diana      Villoria Leon:   Furosemide, the Prevention of Epistaxis and Related Considerations: A Preliminary Evaluation: Submitted for publication,  Irish Veterinary Journal, March, 2012.

  444. Dr. Keith H. Soring, DVMa,   Dr. Kimberly Brewer DVMb,  A J Kind, BA, FAORCc, Dr. Thomas Tobin, MVB, MSc, PhD, MRCVS, DABTd  FOREIGN SUBSTANCES REPORTED IN IOWA    RACING, 2001 2011:  A REVIEW AND ANALYSIS, Submitted for presentation and   publication, American Association of Equine Practitioners Annual Convention, Anaheim CA  December 3rd

Abstracts

1) Tobin T, Sen AK: Ouabain inhibition and ligand affinities of the (Na++K+)-ATPase. Proc Fed Biol Soc 11, 93, 1968.
2) Tobin T, Sen AK: Ligand sensitivity and reversibility of ouabain binding to guinea pig (Na++K+)-ATPase. Proc Fourth Int値 Cong Pharmacology (Basel, 1969), 199, 1968.
3) Tobin T, Brody TM: Alkali metal cation stabilization of [3H]-ouabain binding to (Na++K+)-ATPase. Fed Proc 30, 780, 1971.
4) Tobin T, Akera T, Brody TM: The rates of dissociation of enzyme ouabain and apparent Ki values in (Na++K+)-ATPase from different species. Pharmacologist 13, 308, 1971.
5) Akera T, Tobin T, Brody TM: Influence of assay procedures on the study of ouabain inhibition of (Na++K+)-ATPase in vitro. Pharmacologist 13, 308, 1971.
6) Tobin T, Baskin SI, Akera T, Brody TM: Nucleotide specificity of the phosphorylation and [3H]-ouabain binding reactions of (Na++K+)-ATPase. Fed Proc 31, 583, 1972.
7) Akera T, Baskin SI, Tobin T: Potassium-induced conformational transition of the ouabain (Na++K+)-ATPase complex. Fluorescent probe studies. Fed Proc 31, 591, 1972.
8) Tobin T, Lee Cy, Akera T, Baskin SI, Brody TM: Effects of ethacrynic acid on the duration of transient pulses of [3H]-ouabain binding to guinea pig kidney (Na++K+)-ATPase. Proc Fifth Int値 Congress of Pharmacology, San Francisco, p 243, 1972.
9) Akera T, Lee CY, Baskin SI, Tobin T, Brody TM, Takahashi T: Comparative effects of chlorpromazine and its free radical on cytoplasmic membrane phenomena. Proc Fifth Int値 Congress on Pharmacology, San Francisco, p 3, 1972.
10) Tobin T, Akera T, Baskin SI, Brody TM: The mechanism of the calcium ion inhibition of Na ++k+-ATPase. Proc Fifth Int値 Study Group for Research in Cardiac Metabolism, Winnipeg, p 82, 1972.
11) Akera T, Baskin SI, Tobin T, Brody TM: Cardiac glycosides: Temporal relationship between the inotropic action and binding to and dissociation from Na++K+-ATPase in vitro. Proc Fifth Int値 Study Group for Research on Cardiac Metabolism, Winnipeg, p 80, 1972.
12) Tobin T, Banerjee SP, Sen AK: Ligand sensitivity of [3H]-ouabain binding to native and ethacrynic acid-treated enzyme. Irish J Med Sci, 1972.
13) Baskin SI, Akera T, Tobin T, Brody SL, Puckett CR: Effect of potassium canrenoate on cardiac functions and on Na++K+-ATPase. Fed Proc 32, 811, 1973.
14) Tobin T, Akera T, Baskin SI, Brody TM: [3H]-ouabain binding to Na++K+-ATPase: Inhibition by,-methylene ATP. Fed Proc 32, 709, 1973.
15) Tobin T, Brody TM, Lu MC: Reversible interaction of strophanthidin-bromacetate with the cardiotonic site of (NaK) ATPase. Pharmacologist 15, 224, 1973.
16) Akera T, Tobin T, Ting D, Shieh I-S, Gatti A, Brody TM: Stabilizing effects of potassium on the ouabain-(Na++K+)-ATPase complex. Pharmacologist 15, 224, 1973.
17) Baskin TM, Akera T, Tobin T, Brody TM: Effect of 7,8-dihydrochlorpromazine on Na-K-ATPase and cardiac function. Pharmacologist 15, 224, 1973.
18) Brody TM, Akera T, Tobin T, So RHM: Mechanical shaking of Na-K-ATPase: Loss of catalytic activity and release of specifically bound cardiac glycosides. Pharmacologist 15, 224, 1973.
19) Akera T, Baskin SI, Tobin T, Brody TM, Manian AA: 7,8-Dihydrochloropromazine: (Na++K+)-ATPase inhibition and positive inotropic effect. Presented at Third Int値 Symposium on Phenothiazines and Related Drugs, NIMU, Rockville, MD, June 25-28, 1973.
20) Tobin T, Akera T, Ku D, Brody TM, Lu MC: Strophandihidin-bromacetate: Reversible interaction with the cardiotonic steroid binding site of Na++K+-ATPase. Third Annual Michigan Cardiovascular Research Forum, Ann Arbor, Sept 25, 1973.
21) Tobin T: Studies on the two phosphoenzyme conformations of Na++K+-ATPase. NY Acad Sci Meeting on NA++K+-ATPase. NY Acad Sci, NY, Nov 1973.
22) Tobin T: Lithium ion and Na++K+-ATPase: A molecular basis for its pharmacological actions. Winter Brain Research Conference, Steamboat Springs, CO, January 1974.
23) Tobin T, Akera T, Brody TM: Lithium, rubidium and Na ++K+-ATPase: A molecular basis for their pharmacological actions. Fed Proc 33, 483, 1974.
24) Akera T, Tobin T, Brody TM: Ouabain-Na++K+-ATPase complex: Evidence for more than two forms. Fed Proc 33, 491, 1974.
25) Tobin T, Akera T, Taneja HR, Brody TM: Affinity labeling of Na ++K+-ATPase. I. Strophanthidin 3,5-bisparabenzylbenzoate, a photochemical analogue of strophanthidin. Canad Fed Biol Societies, presentation, Societies Meeting, Hamilton, Ontario, June 1974.
26) Ku D, Akera T, Tobin T, Brody TM: Effects of monovalent cations on cardiac Na, K-ATPase activity and on contractile force. Pharmacologist 15, 326, 1974.
27) Tobin T, Akera T, Ku D, Brody TM: Cassaine: Its mechanism of inhibition of Na++K+-ATPase and the relationship of this inhibition to its cardiotonic actions. Fourth Annual Michigan Cardiovascular Research Conference, Detroit, MI, September 20, 1974.
28) Akera T, Young RC, Tobin T, Brody TM: Estimation of maximal ouabain binding to Na, K-ATPase and tissue differences in enzyme turnover. Pharmacologist 16, 293, 1974.
29) Tobin T, Akera T, Brody TM: Shadowmycin a nucleotide site directed inhibitor of Na ++K+-ATPase. Fed Proc 34, 715, 1975.
30) Tobin T, Abramson H: Affinity labeling of Na ++K+-ATPase: Digoxigenin-3-12-di-bromacetate, an alkylating derivative of digoxigenin. Presented at 1975 Winter Conference for Brain Research, Steamboat Springs, CO.
31) Ku D, Akera T, Tobin T, Brody TM: Comparative species studies on the effect of monovalent cations and ouabain on cardiac Na++K+-ATPase and contractile force. Fed Proc 34, 792, 1975.
32) Tobin T, Blake JW: The pharmacokinetics and behavioral effects of procaine in Thoroughbred horses. Second Int値 Doping Research and Control Conference, Newmarket, England, May 1976.
33) Roberts BL, Blake JW, Tobin T: Pharmacodynamics and drug interactions of furosemide in the horse. 1st Int値 Toxicology Conference, Toronto, Ontario, 1977.
34) Miller JR, Blake JW, Tobin T: Detection and pharmacokinetics of apomorphine in the horse. 1st Int値 Toxicology Conference, Toronto, Ontario, 1977.
35) Widest SA, Akera T, Brody TM, Tobin T: Effects of potassium on the inotropic action of digoxin. Fed Mtgs, Chicago, 1977.
36) White CG, Woods WE, Tobin T: The pharmacology of reserpine in the horse. II. Effects of reserpine and imipramine on platelet uptake of serotonin. 7th Int値 Congress of Pharmacology, Paris, France, 1978.
37) White CG, Woods WE, Tobin T: Biochemical and behavioral effects of reserpine in the horse. For presentation and publication, SOT Mtg, New Orleans, March 1979.
38) Shults T, Combie J, Dougherty J, Tobin T: Pharmacokinetics and behavioral effects of cocaine in the horse. For presentation and publication, SOT Mtg, New Orleans, LA, March 1979.
39) Combie J, Shults T, Nugent E, Tobin T: Pharmacokinetics and behavioral effects of fentanyl in the horse. For presentation and publication, SOT Mtg, New Orleans, LA, March 1979.
40) Combie J, Shults, Tobin T: The pharmacokinetics and behavioral effects of fentanyl and other narcotic analgesics in the horse. Abstr, Third Int値 Symposium on Equine Medication Control, Lexington, KY, 1979.41.Shults T, Combie J, Dougherty J, Tobin T: Variable interval scheduling in the horse: A sensitive measure of behavior. Ibid, 1979.
41) Chay S, Woods WE, Tobin T: The pharmacokinetics of flunixin in the horse. Third Symposium of American Academy of Veterinary Pharmacology and Therapeutics, Ohio State University, Columbus, 1982.
42) Weld JM, Combie J, Nugent T, Oeltgen P, Tobin T: Hemorrhagic and endotoxin shock in horses: Effects of naloxone treatment on cardiovascular performance. Ibid, 1982.
43) Chay S, Woods WE, Tobin T: The pharmacokinetics and blood levels of furosemide after intravenous administration. Fifth Int値 Conf Control of Use of Drugs in Race Horses. Toronto, Canada, 1983.
44) Houston TE, Tobin T, Blake JW: The effect of urinary pH on oxyphenbutazone concentrations in equine urine. Ibid, 1983.
45) Collett LJ, Kamerling S, Nugent T, Weckman TJ, Woods WE, DeQuick D, Tobin T: Clearance times and behavioral effects of clenbuterol in the horse. Ibid. 1983.
46) Kamerling S, DeQuick D, Nugent T, Weckman TJ, Tobin T: Phenylbutazone: Lack of effect on normal cutaneous pain perception in the horse. Ibid, 1983.

ABSTRACTS WERE NOT RECORDED 1984 THRU 1990 

47) Jeganathan, A., Park, O.S., Steviov, I., Ravard, A., Vasudevan, S., Yang, J., Stanley, S., Woods, W.E., Tai, H-H., Blake, J.W., Tobin, T., and Watt, D.: Strategies for the development of effective ELISA tests for controlling medicants and illegal drugs in racing horses. Submitted for presentation at The World Veterinary Conference XXIV, Rio De Janeiro, Brazil, Aug. 1991.
48) Yang, J., Stanley, S., Jeganathan, A., Park, O.S., Steviov, I., Ravard, A., Vasudevan, S., Woods, W.E., Watt, D., Tai, H-H., Blake, J.W., and Tobin, T.: High sensitivity ELISA tests for drugs abused in racing horses. Submitted for presentation at The World Veterinary Conference XXIV, Rio De Janeiro, Brazil Aug., 1991. 
49) Roth, L., Harbison, R.D., James, R.C., Tobin, T., and Roberts, S.M.: Localization of cocaine and metabolites in liver sections: Effect of enzyme inducer pretreatment. Submitted for publication and presentation, SOT Mtg, Seattle, WA, February 1992.
50) Stanley, S.D., Huffman, M., Sadove, D., Cole, N., Diana, J.N., Tai, H-H., Gairola, C.G. and Tobin, T. Salivary levels of cotinine and wound healing in post surgical patients: A preliminary report. Submitted for publication and presentation, SOT Mtg, Seattle, WA, February 1992.
51) Gairola, C.G., Stanley, S.D., Diana, J.N., Tai, H-H. and Tobin, T.: Urinary excretion of cotinine in chronically cigarette smoke-exposed mice. Submitted for publication and presentation, SOT Mtg, Seattle, WA, February 1992.
52) Yang, J.M., Woods, W.E., Tai, H-H., Watt, D.S. and Tobin, T.: Development of highly sensitive ELISA for fluphenazine in horses. Submitted for publication and presentation, SOT Mtg, Seattle, WA, February 1992.
53) Woods, W.E., Stanley, S., Yang, J-M., Cook, D., Gerkin, D., Detra, R., Sams, R., Watt, D., Tai, H-H., and Tobin, T.: ELISA detection of azaperone the race-horse. Submitted for presentation at The Ninth International Conference of Racing Analysts and Veterinarians. New Orleans, LA, March,1992. 
54) Stanley, S.D., Wood, T.W., Selonen, J.S., Yang, J-M., Watt, D., Tai, H- H., and Tobin, T.: Detomidine clearance in the horse as determined by ELISA. Submitted for presentation at The Ninth International Conference of Racing Analyst and Veterinarians. New Orleans, LA, March, 1992.
55) Yang, J-M., Stanley, S., Woods, W.E., Cook, D., Tai, H-H., Watt, D., and Tobin, T.: The procaine ELISA screening in racing horses. Submitted for presentation at The Ninth International Conference of Racing Analyst and Veterinarians. New Orleans, LA, March, 1992.
56) Roth L, Harbison R, James R, Tobin T, Roberts S. Cocaine hepatotoxicity: Influence of hepatic enzyme inducing and inhibiting agents on the site of necrosis. Submitted for publication to SOT, Seattle, Washington, 1992.
57) Stanley, SC, Huffman, M, Sadove, Rn, Cole, N, Diana JN, Gairola CG, Tai H-H and Tobin T: Salivary levels of cotinine and wound healing in post surgical patients: A preliminary report. Society of Toxicology. Annual Meeting, Seattle, Washington, February, 1992.
58) Determination of highest no-effect doses (HNEDS) for local anesthetic responses to procaine, cocaine, bupivacaine and benzocaine in thoroughbred mares.
59) Character and duration of pharmacological effects of intravenous isoxsuprine.
60) Significance of procaine residues in post-race urine samples.
61) Effect of -phenyl-tert-butylnitrone on endotoxin toxemia in horses.
62) The pharmacokinetics and bioavailability of amantadine in the horse: A preliminary report.
63) An analysis of prohibited substances in Kentucky with emphasis on strategies for practitioners to avoid problems.
64) Quantification of the sedative effect of amitraz in the horse.
65) An overview of dietary, environmental and endogenous substances of regulatory concern in racing horses.
66) Fifth Symposium of Environmental Toxicology and Risk Assessment: Biomarkers and Risk Assessment. An Overview of Dietary, Environmental and Endogenous Substances of Regulatory Concern in Racing Horses.
67) Testing for Drugs, Medications and Other Substances in Racing Horses.
68) Quantification of the Sedative Effect of Amitraz in the Horse.
69) Character and Duration of Pharmacological Effects of Intravenous Isoxsuprine.
70) Significance of Procaine Residues in Post Race Urine Samples.
71) Effect of a-Phenyl-tert-butylnitrone on Endotoxin Toxemia in Horses.
72) Determination of Highest No-Effect Doses (HNEDS) for Local Anesthetic Responses to 
73) Procaine, Cocaine, Bupivacaine, and Benzocaine in Thoroughbred Mares.
74) Quantitation of the Locomoter Effect of Therapeutic Medication in a Behavior Chamber.
75) ELISA and GC/MS Detection of Cocaine.
76) Testing for Therapeutic medications, Environmental and Dietary Substances in Racing Horses: Outcomes of the Workshop Held in Lexington, August, 1994.
77) A Review of a Consequence of Highly Sensitive Drug Testing: The Need for Data on Analytical/ Pharmacological Relationships for Therapeutic Medications.
78) Lidocaine: Dose Response Relationships and Analytical Detection in Horses.
79) Pharmacokinetics and Bioavailability of Amantadine in the Horse: A Preliminary Report.
80) Analytical Detection and Preliminary Pharmacokinetics of Toltrazuril and Diclazuril in the Horse.
81) A Clinical Report of Diclazuril Treatment for Equine Protozoal Myeloencephalitis.
82) Diclazuril and Equine Protozoal Myeloencephalitis.
83) Development of an Equine Behavior Chamber and Effects of Amitraz, Detomidine, and Acepromazine on Spontaneous Locomotor Activity.
84) Preliminary Pharmacokinetics of Diclazuril and Toltrazuril in the Horse.
85) Therapeutic Efficacy of Rimantadine HCL in Experimentally Induced Influenza: An Illness in Horses.
86) Review of a Consequence of Highly Sensitive Drug Testing: The Need for Data on Analytical-Pharmacological Relationships for Therapeutic Medications.
87) Testing for Therapeutic Medications: Analytical / Pharmacological Relationships and the Need for Limitations on the Sensitivity of Testing for Certain Agents- A Work in Progress. Jan. 22, 1998.
88) Detection and Quantitation of 2-Hydroxylidocaine in Horse Urine.
89) ELISA Assay for Fluoxetine.
90) Detection and Quantitation of 3-Hydroxybupivacaine in Horse Urine.
91) Detection and Quantitation of 3-Hydroxymepivacaine in Horse Urine.
92) Karpiesiuk W, Lehner AF, Fisher M, Tobin T: Synthesis of the Equine Metabolites of Four Xylidide Local Anesthetics. 65th Annual Meeting AORC, March, 1999.
93) Harkins JD, Holtz C, Boyles J, Woods E, Lehner AF, Carter W, Karpiesiuk W, Fisher M, Tobin T: Behavioral and Cardiac Effects of Clenbuterol and Furosemide in the Horse: An Overview. 65th Annual Meeting AORC, March, 1999.
94) Dirikolu L, Lehner F, Harkins JD, Woods WE, Carter WG, Karpiesiuk W, Boyles J, Fisher M, Tobin T: Identification of Lidocaine and Its Metabolites in Post Administration Equine Urine By Elisa and MS/MS. 65th Annual Meeting AORC, March, 1999.
95) Woods WE, Lehner A, Bosken J, Holtz C, Fisher M, Tobin T: Elisa and GC/MS Detection of Isoxsuprine in Equine Urine. 65th Annual Meeting AORC, March, 1999.
96) Carter WG, Lehner AF, Dirikolu L, Woods WE, Karpiesiuk W, Harkins JD, Boyles JE, Jacobs J, Fisher M, Tobin T: Detection and Characterization of Ropivacaine Metabolites in Horse Urine. 65th Annual Meeting AORC, March, 1999.
97) Holtz C, Woods WE, Dirikolu L, Lehner F, Carter W, Harkins JD, Karpiesiuk W, Fisher M, Tobin T: Clenbuterol in the Horse: A Preliminary Analytical Report. 65th Annual Meeting AORC, March, 1999.
98) Lehner AF, Hunsucker A, Bosken JM, Harkins JD, Woods WE, Karpiesiuk W, Carter WG, Boyles J, Fisher M, Tobin T: Further Characterization of Equine Isoxsuprine Metabolites By Electrospray Ionization Tandem Mass Spectrometry. 65th Annual Meeting AORC, March, 1999.
99) Bosken JM, Lehner AF, Hunsucker A, Harkins JD, Woods WE, Karpiesiuk W, Carter WG, Boyles J, Fisher M, Tobin T: Isoxsuprine Conjugates Identified in Equine Urine By Direct Injection ESI/MS/MS. 65th Annual Meeting AORC, March 1999.
100) Boyles J, Woods WE, Harkins D, Lehner F, Karpiesiuk W, Dirikolu L, Bosken J, Carter W, Jacobs J, Fisher M, Tobin T: Procedures and Quality Assurance Aspects of the Testing Integrity Program. 65th Annual Meeting AORC, March 1999.
101) Harkins, JD and Tobin T. Highest No-Effect Dose for Pharmacological Responses to Acepromazine in the Horse: A Preliminary Communication. Research Committee of the Testing Integrity Program, May 2002.
102) Tobin T, McDowell K, Hughes C, Lehner A, Crutchfield J, Harkins JD, Dirikolu L, Sebastian M, Harrison L, Williams N, Smith R, Webb B, Bush L, Newman K, Allman R, Dwyer R and Powell D: The Kentucky 2001 Mare Reproductive Loss Syndrome: Overview and Preliminary Toxicological Approaches. 14th International Conference of Racing Analysts and Veterinarians, July 2002.
103) Dirikolu L, Lehner AF, Hughes C, Karpiesiuk W, Camargo FC, Harkins JD, Woods WE, Bosken J, Boyles J, Troppmann A, Fisher M and Tobin T: Detection, Quantification and Pharmacokinetics of Furosemide (Salix) Following Intravenous Administrations in Horses. 14th International Conference of Racing Analysts and Veterinarians, July 2002.
104) Harkins JD and Tobin T: Pharmacodynamics of Guanabenz and Related  Agonists. 14th International Conference of Racing Analysts and Veterinarians, July 2002.
105) Lehner A.F, Hughes C, Woods WE, Harkins JD, Karpiesiuk W, Dirikolu L, Bosken J, Boyles J, Troppmann A, Fisher M and Tobin T: Proposed Methodology for the Detection of Oxyglobin in Equine Plasma. 14th International Conference of Racing Analysts and Veterinarians, July 2002.
106) Karpiesiuk W, Lehner AF, Dirikolu L, Fisher M, Tobin T: Synthesis and Characterization of Deuterated Standard of Furosemide (Salix). 14th International Conference of Racing Analysts and Veterinarians, July 2002.
107) Hughes C, Lehner A, Crutchfield J, Woods W, Harkins J, Karpiesiuk W, Dirikolu L, Sebastian M, Troppmann A, Boyles J, Bosken J, Harrison L, Tobin T: Analytical Detection and 哲ormal Population Data of Cyanide and Thiocyanate in Equine Blood and Serum. 14th International Conference of Racing Analysts and Veterinarians, July 2002.
108) Camargo F, Dirikolu L, Sebastian M, Hughes C, Crutchfield J, Harkins D, Boyles J, Troppmann A, McDowell K, Harrison L and Tobin T: The Toxicokinetics of Cyanide and Mandelonitrile in the Horse and Their Relevance to the Mare Reproductive Loss Syndrome. 14th International Conference of Racing Analysts and Veterinarians, July 2002.
109) Dirikolu L, Mollett BA, Woods WE, Bratton C, Lehner AF, Karpiesiuk W, Hughes C, Boyles J, Harkins JD, Troppmann A, and Tobin T: ELISA 泥etection Times of Albuterol after Torpex Administration: A Preliminary Report. 14th International Conference of Racing Analysts and Veterinarians, July 2002.
110) Certified Reference Standards and Stable Isotope Internal Standards for Equine Medication Regulation. Seventh Kentucky Innovation and Entrepreneurship Conference (KSEF). Louisville, KY. May 2011.
111) 2. Equine Medication Regulation: Stable Isotope Internal Standards and Certified Reference Standards. Sixth Kentucky Innovation and Entrepreneurship Conference (KSEF). Lexington, KY. April 2010.